{ "version": "2.2", "instance": { "d118828d10q.htm": { "nsprefix": "teva", "nsuri": "http://www.tevapharm.com/20260730", "dts": { "inline": { "local": [ "d118828d10q.htm" ] }, "schema": { "local": [ "teva-20260730.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/currency/2025/currency-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd", "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd", "https://xbrl.sec.gov/exch/2025/exch-2025.xsd", "https://xbrl.sec.gov/naics/2025/naics-2025.xsd", "https://xbrl.sec.gov/sic/2025/sic-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] } }, "keyStandard": 255, "keyCustom": 108, "axisStandard": 34, "axisCustom": 7, "memberStandard": 52, "memberCustom": 91, "hidden": { "total": 18, "http://xbrl.sec.gov/dei/2025": 6, "http://fasb.org/us-gaap/2025": 12 }, "contextCount": 613, "entityCount": 1, "segmentCount": 146, "elementCount": 853, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2025": 1243, "http://xbrl.sec.gov/dei/2025": 30, "http://xbrl.sec.gov/ecd/2025": 18 }, "report": { "R1": { "role": "http://www.tevapharm.com/role/CoverPage", "longName": "1001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "longName": "1002 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "PAsOn06_30_2026", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn06_30_2026", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "PAsOn06_30_2026", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn06_30_2026", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "longName": "1004 - Statement - Consolidated Statements of Income (Loss)", "shortName": "Consolidated Statements of Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "unique": true } }, "R5": { "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical", "longName": "1005 - Statement - Consolidated Statements of Income (Loss) (Parenthetical)", "shortName": "Consolidated Statements of Income (Loss) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "P04_01_2025To06_30_2025", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true }, "uniqueAnchor": null }, "R6": { "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "longName": "1006 - Statement - Consolidated Statements of Comprehensive Income (Loss)", "shortName": "Consolidated Statements of Comprehensive Income (Loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "unique": true } }, "R7": { "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical", "longName": "1007 - Statement - Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)", "shortName": "Consolidated Statements of Comprehensive Income (Loss) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "P04_01_2025To06_30_2025", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity", "longName": "1008 - Statement - Consolidated Statements of Changes in Equity", "shortName": "Consolidated Statements of Changes in Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "PAsOn12_31_2024", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2024", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical", "longName": "1009 - Statement - Consolidated Statements of Changes in Equity (Parenthetical)", "shortName": "Consolidated Statements of Changes in Equity (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "P04_01_2026To06_30_2026_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis", "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P04_01_2026To06_30_2026_CommonStockMemberusgaapStatementEquityComponentsAxis_MaximumMembersrtRangeAxis", "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows", "longName": "1010 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "10", "firstAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "unique": true } }, "R11": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true }, "uniqueAnchor": null }, "R12": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026_EvanLippmanEvpBusinessDevelopmentMemberecdTradingArrAxis", "name": "ecd:TrdArrIndName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026_EvanLippmanEvpBusinessDevelopmentMemberecdTradingArrAxis", "name": "ecd:TrdArrIndName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.tevapharm.com/role/BasisOfPresentation", "longName": "999001 - Disclosure - Basis of presentation", "shortName": "Basis of presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.tevapharm.com/role/CertainTransactions", "longName": "999002 - Disclosure - Certain transactions", "shortName": "Certain transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "teva:CertainTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "teva:CertainTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers", "longName": "999003 - Disclosure - Revenue from contracts with customers", "shortName": "Revenue from contracts with customers", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.tevapharm.com/role/Inventories", "longName": "999004 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.tevapharm.com/role/IdentifiableIntangibleAssets", "longName": "999005 - Disclosure - Identifiable Intangible Assets", "shortName": "Identifiable Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.tevapharm.com/role/Goodwill", "longName": "999006 - Disclosure - Goodwill", "shortName": "Goodwill", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.tevapharm.com/role/DebtObligations", "longName": "999007 - Disclosure - Debt obligations", "shortName": "Debt obligations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities", "longName": "999008 - Disclosure - Derivative instruments and hedging activities", "shortName": "Derivative instruments and hedging activities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies", "longName": "999009 - Disclosure - Legal Settlements and Loss Contingencies", "shortName": "Legal Settlements and Loss Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.tevapharm.com/role/CommitmentsAndContingencies", "longName": "999010 - Disclosure - Commitments and contingencies", "shortName": "Commitments and contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.tevapharm.com/role/IncomeTaxes", "longName": "999011 - Disclosure - Income taxes", "shortName": "Income taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems", "longName": "999012 - Disclosure - Other assets impairments, restructuring and other items", "shortName": "Other assets impairments, restructuring and other items", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "teva:OtherExpensesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "teva:OtherExpensesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.tevapharm.com/role/EarningsLossPerShare", "longName": "999013 - Disclosure - Earnings (Loss) per share", "shortName": "Earnings (Loss) per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss", "longName": "999014 - Disclosure - Accumulated other comprehensive income (loss)", "shortName": "Accumulated other comprehensive income (loss)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.tevapharm.com/role/Segments", "longName": "999015 - Disclosure - Segments", "shortName": "Segments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.tevapharm.com/role/FairValueMeasurement", "longName": "999016 - Disclosure - Fair value measurement", "shortName": "Fair value measurement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.tevapharm.com/role/CertainTransactionsTables", "longName": "999017 - Disclosure - Certain transactions (Tables)", "shortName": "Certain transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:AssetAcquisitionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "teva:CertainTransactionsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:AssetAcquisitionTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "teva:CertainTransactionsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables", "longName": "999018 - Disclosure - Revenue from contracts with customers (Tables)", "shortName": "Revenue from contracts with customers (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.tevapharm.com/role/InventoriesTables", "longName": "999019 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables", "longName": "999020 - Disclosure - Identifiable Intangible Assets (Tables)", "shortName": "Identifiable Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.tevapharm.com/role/GoodwillTables", "longName": "999021 - Disclosure - Goodwill (Tables)", "shortName": "Goodwill (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.tevapharm.com/role/DebtObligationsTables", "longName": "999022 - Disclosure - Debt obligations (Tables)", "shortName": "Debt obligations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables", "longName": "999023 - Disclosure - Derivative instruments and hedging activities (Tables)", "shortName": "Derivative instruments and hedging activities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables", "longName": "999024 - Disclosure - Other assets impairments, restructuring and other items (Tables)", "shortName": "Other assets impairments, restructuring and other items (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "teva:OtherExpensesTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "teva:OtherExpensesTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.tevapharm.com/role/EarningsLossPerShareTables", "longName": "999025 - Disclosure - Earnings (Loss) per share (Tables)", "shortName": "Earnings (Loss) per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "longName": "999026 - Disclosure - Accumulated other comprehensive income (loss) (Tables)", "shortName": "Accumulated other comprehensive income (loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.tevapharm.com/role/SegmentsTables", "longName": "999027 - Disclosure - Segments (Tables)", "shortName": "Segments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.tevapharm.com/role/FairValueMeasurementTables", "longName": "999028 - Disclosure - Fair Value Measurement (Tables)", "shortName": "Fair Value Measurement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "longName": "999029 - Disclosure - Certain Transactions - Other Transactions - Additional Information (Detail)", "shortName": "Certain Transactions - Other Transactions - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "PAsOn06_18_2026", "name": "teva:PercentageOfDiscountRateAppliedToTheCashFlows", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "div", "teva:CertainTransactionsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn06_18_2026", "name": "teva:PercentageOfDiscountRateAppliedToTheCashFlows", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "div", "teva:CertainTransactionsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.tevapharm.com/role/CertainTransactionsSummaryOfAssetsAcquiredLiabilitiesAssumedDetail", "longName": "999030 - Disclosure - Certain transactions - Summary of Assets Acquired, liabilities Assumed (Detail)", "shortName": "Certain transactions - Summary of Assets Acquired, liabilities Assumed (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "P06_10_2026To06_10_2026_EmalexBiosciencesMemberusgaapAssetAcquisitionAxis", "name": "teva:AssetAcquisitionConsiderationTransferredCash", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:AssetAcquisitionTableTextBlock", "teva:CertainTransactionsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P06_10_2026To06_10_2026_EmalexBiosciencesMemberusgaapAssetAcquisitionAxis", "name": "teva:AssetAcquisitionConsiderationTransferredCash", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:AssetAcquisitionTableTextBlock", "teva:CertainTransactionsDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail", "longName": "999031 - Disclosure - Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail)", "shortName": "Certain Transactions - Business Acquisitions - Summary of Major Classes of Assets and Liabilities Included as Held for Sale (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "PAsOn06_30_2026", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn06_30_2026", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "teva:ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail", "longName": "999032 - Disclosure - Revenue from Contracts with Customers - Additional Information (Detail)", "shortName": "Revenue from Contracts with Customers - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026_USsrtStatementGeographicalAxis", "name": "teva:SalesReservesAndAllowancesToCustomersPercentage", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026_USsrtStatementGeographicalAxis", "name": "teva:SalesReservesAndAllowancesToCustomersPercentage", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail", "longName": "999033 - Disclosure - Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail)", "shortName": "Revenue from Contracts with Customers - Summary of Disaggregation of Revenues by Major Revenue Streams (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P04_01_2026To06_30_2026_ProductMembersrtProductOrServiceAxis", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "unique": true } }, "R46": { "role": "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail", "longName": "999034 - Disclosure - Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail)", "shortName": "Revenue from Contracts with Customers - Schedule of Sales Reserves and Allowances (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "PAsOn12_31_2025", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "teva:SalesReservesAndAllowancesCurrentTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2025", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "teva:SalesReservesAndAllowancesCurrentTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail", "longName": "999035 - Disclosure - Inventories - Summary of Inventories (Detail)", "shortName": "Inventories - Summary of Inventories (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "PAsOn06_30_2026", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn06_30_2026", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "longName": "999036 - Disclosure - Identifiable Intangible Assets - Additional Information (Detail)", "shortName": "Identifiable Intangible Assets - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "PAsOn12_31_2024", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2024", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail", "longName": "999037 - Disclosure - Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail)", "shortName": "Identifiable Intangible Assets - Summary of Identifiable Intangible Assets (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "PAsOn06_30_2026", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn06_30_2026", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail", "longName": "999038 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail)", "shortName": "Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "PAsOn12_31_2025", "name": "us-gaap:Goodwill", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "div", "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2024", "name": "us-gaap:Goodwill", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "unique": true } }, "R51": { "role": "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail", "longName": "999039 - Disclosure - Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail)", "shortName": "Goodwill - Summary of Changes in the Carrying Amount of Goodwill by Segment (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "PAsOn06_30_2026", "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-8", "ancestors": [ "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss", "div", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn06_30_2026", "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-8", "ancestors": [ "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss", "div", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail", "longName": "999040 - Disclosure - Debt Obligations - Schedule of Short-term Debt (Detail)", "shortName": "Debt Obligations - Schedule of Short-term Debt (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "PAsOn06_30_2026", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShortTermDebtTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn06_30_2026", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShortTermDebtTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtParentheticalDetail", "longName": "999041 - Disclosure - Debt Obligations - Schedule of Short-term Debt (Parenthetical) (Detail)", "shortName": "Debt Obligations - Schedule of Short-term Debt (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "PAsOn06_30_2026_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis", "name": "us-gaap:ShortTermDebtWeightedAverageInterestRate", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfShortTermDebtTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn06_30_2026_ConvertibleDebtMemberusgaapShortTermDebtTypeAxis", "name": "us-gaap:ShortTermDebtWeightedAverageInterestRate", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfShortTermDebtTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "longName": "999042 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Detail)", "shortName": "Debt Obligations - Schedule of Senior Notes and Loans (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "PAsOn06_30_2026", "name": "us-gaap:SeniorNotes", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "teva:LongTermDebtExcludingConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn06_30_2026", "name": "us-gaap:SeniorNotes", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "teva:LongTermDebtExcludingConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail", "longName": "999043 - Disclosure - Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail)", "shortName": "Debt Obligations - Schedule of Senior Notes and Loans (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "PAsOn06_30_2026_SubsidiarySeniorNotesDue2026MemberusgaapDebtInstrumentAxis", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "div", "td", "tr", "table", "teva:LongTermDebtExcludingConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn06_30_2026_SubsidiarySeniorNotesDue2026MemberusgaapDebtInstrumentAxis", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "div", "td", "tr", "table", "teva:LongTermDebtExcludingConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "longName": "999044 - Disclosure - Debt Obligations - Additional Information (Detail)", "shortName": "Debt Obligations - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "PAsOn06_30_2026", "name": "teva:LongTermDebtCurrencyPortionUSD", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn06_30_2026", "name": "teva:LongTermDebtCurrencyPortionUSD", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail", "longName": "999045 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail)", "shortName": "Derivative Instruments and Hedging Activities - Summary of Classification and Fair Values of Derivative Instruments (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "PAsOn06_30_2026_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn06_30_2026_DesignatedAsHedgingInstrumentMemberusgaapHedgingDesignationAxis_ForeignExchangeContractMemberusgaapDerivativeInstrumentRiskAxis_OtherCurrentAssetsMemberusgaapBalanceSheetLocationAxis", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail", "longName": "999046 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Pre-tax (Gains) Losses From Derivatives Designated in Cash Flow Hedging Relationships (Detail)", "shortName": "Derivative Instruments and Hedging Activities - Summary of Pre-tax (Gains) Losses From Derivatives Designated in Cash Flow Hedging Relationships (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "teva:UnrealizedGainLossOnCashFlowHedgingInstrument", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "teva:DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "teva:UnrealizedGainLossOnCashFlowHedgingInstrument", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "teva:DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail", "longName": "999047 - Disclosure - Derivative Instruments and Hedging Activities - Summary of Pre-tax (Gains) Losses From Derivatives Not Designated in as Hedging Instruments (Detail)", "shortName": "Derivative Instruments and Hedging Activities - Summary of Pre-tax (Gains) Losses From Derivatives Not Designated in as Hedging Instruments (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "P04_01_2026To06_30_2026_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis", "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P04_01_2026To06_30_2026_FinancialExpensesMemberusgaapIncomeStatementLocationAxis_NondesignatedMemberusgaapHedgingDesignationAxis", "name": "us-gaap:GainLossOnDerivativeInstrumentsNetPretax", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "longName": "999048 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Detail)", "shortName": "Derivative Instruments and Hedging Activities - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "PAsOn06_30_2026", "name": "teva:RevenuesOtherThanUsd", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "teva:TransactionsTerminationLossSettled", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "unique": true } }, "R61": { "role": "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail", "longName": "999049 - Disclosure - Legal Settlements and Loss Contingencies - Additional Information (Detail)", "shortName": "Legal Settlements and Loss Contingencies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:LitigationSettlementExpense", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "div", "us-gaap:LegalMattersAndContingenciesTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:LitigationSettlementExpense", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "div", "us-gaap:LegalMattersAndContingenciesTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail", "longName": "999050 - Disclosure - Commitments and Contingencies - Contingencies - Additional Information (Detail)", "shortName": "Commitments and Contingencies - Contingencies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "P12_01_2011To12_31_2011", "name": "teva:AnnualSalesOfEffexor", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-8", "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P12_01_2011To12_31_2011", "name": "teva:AnnualSalesOfEffexor", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-8", "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail", "longName": "999051 - Disclosure - Income Taxes - Additional Information (Detail)", "shortName": "Income Taxes - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "teva:IncomeLossFromContinuingOperationsBeforeIncomeTaxes", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "unique": true } }, "R64": { "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail", "longName": "999052 - Disclosure - Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail)", "shortName": "Other assets impairments, restructuring and other items - Schedule of Other Assets Impairments, Restructuring and Other Items (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "teva:OtherExpensesTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "teva:OtherExpensesTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail", "longName": "999053 - Disclosure - Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail)", "shortName": "Other assets impairments, restructuring and other items - Components of costs associated with restructuring plan including costs related to exit and disposal activities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:RestructuringCharges", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "teva:OtherExpensesTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P04_01_2026To06_30_2026_EmployeeSeveranceMemberusgaapRestructuringCostAndReserveAxis", "name": "us-gaap:RestructuringCharges", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "teva:ScheduleOfRestructuringChargesTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "unique": true } }, "R66": { "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail", "longName": "999054 - Disclosure - Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail)", "shortName": "Other assets impairments, restructuring and other items - Summary of Restructuring Accruals (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "PAsOn12_31_2025", "name": "us-gaap:RestructuringReserve", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2025", "name": "us-gaap:RestructuringReserve", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail", "longName": "999055 - Disclosure - Other assets impairments, restructuring and other items - Additional Information (Detail)", "shortName": "Other assets impairments, restructuring and other items - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:TangibleAssetImpairmentCharges", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "div", "teva:OtherExpensesTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:TangibleAssetImpairmentCharges", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "div", "teva:OtherExpensesTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail", "longName": "999056 - Disclosure - Earnings (Loss) per share - Schedule of Earnings per Share (Detail)", "shortName": "Earnings (Loss) per share - Schedule of Earnings per Share (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail", "longName": "999057 - Disclosure - Earnings (Loss) per share - Additional Information (Detail)", "shortName": "Earnings (Loss) per share - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock", "unitRef": "Unit_shares", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "unique": true } }, "R70": { "role": "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "longName": "999058 - Disclosure - Accumulated other comprehensive income (loss) (Detail)", "shortName": "Accumulated other comprehensive income (loss) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2025_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis", "name": "us-gaap:AociTaxAttributableToParent", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "unique": true } }, "R71": { "role": "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail", "longName": "999059 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Parenthetical) (Detail)", "shortName": "Accumulated Other Comprehensive Income (Loss) (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "P01_01_2025To06_30_2025", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2025To06_30_2025", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail", "longName": "999060 - Disclosure - Segments - Summary of Segment Profit (Detail)", "shortName": "Segments - Summary of Segment Profit (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:OperatingIncomeLoss", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:AdjustmentForAmortization", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "unique": true } }, "R73": { "role": "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail", "longName": "999061 - Disclosure - Segments - Schedule of Revenues by Major Products and Activities (Detail)", "shortName": "Segments - Schedule of Revenues by Major Products and Activities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "P04_01_2026To06_30_2026", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "P04_01_2026To06_30_2026_GenericsMediciansIncludingOtcAndBiosimilarsMembersrtProductOrServiceAxis_UnitedStatesSegmentMemberusgaapStatementBusinessSegmentsAxis", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "teva:ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "unique": true } }, "R74": { "role": "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail", "longName": "999062 - Disclosure - Segments - Additional Information (Detail)", "shortName": "Segments - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Unit_Segment", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P01_01_2026To06_30_2026", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "Unit_Segment", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.tevapharm.com/role/SegmentsParentheticalDetail", "longName": "999063 - Disclosure - Segments (Parenthetical) (Detail)", "shortName": "Segments (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "P04_01_2026To06_30_2026_UnitedStatesSegmentMemberusgaapStatementBusinessSegmentsAxis", "name": "us-gaap:Depreciation", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "div", "td", "tr", "table", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P04_01_2026To06_30_2026_UnitedStatesSegmentMemberusgaapStatementBusinessSegmentsAxis", "name": "us-gaap:Depreciation", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "div", "td", "tr", "table", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail", "longName": "999064 - Disclosure - Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail)", "shortName": "Fair Value Measurement - Summary of Financial Items Carried at Fair Value (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "PAsOn06_30_2026", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn06_30_2026", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R77": { "role": "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail", "longName": "999065 - Disclosure - Fair value measurement - Additional Information (Detail)", "shortName": "Fair value measurement - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "PAsOn06_30_2026", "name": "teva:PercentageOfIncreaseDecreaseInContingentConsiderationLiabilities", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn06_30_2026", "name": "teva:PercentageOfIncreaseDecreaseInContingentConsiderationLiabilities", "unitRef": "Unit_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail", "longName": "999066 - Disclosure - Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail)", "shortName": "Fair Value Measurement - Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "PAsOn12_31_2025", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn12_31_2025", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } }, "R79": { "role": "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail", "longName": "999067 - Disclosure - Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail)", "shortName": "Fair Value Measurement - Summary of Financial Instrument Measured on a Basis Other Than Fair Value (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "PAsOn06_30_2026", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "PAsOn06_30_2026", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "Unit_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d118828d10q.htm", "first": true, "unique": true } } }, "tag": { "teva_AbingworthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AbingworthMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Abingworth [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableTradeCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsPayableTradeCurrent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Trade, Current", "verboseLabel": "Accounts payables", "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r22", "r58" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsReceivableMember", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r1068", "r1446" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivables, net of allowance for credit losses of $75 million and $81 million as of June 30, 2026 and December 31, 2025, respectively", "definitionGuidance": "Accounts receivables, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1457" ] }, "teva_AccountsReceivableSecuritizationFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AccountsReceivableSecuritizationFacilityMember", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable Securitization Facility [Member]", "terseLabel": "Accounts Receivable Securitization Facility [Member]", "documentation": "Accounts receivable securitization facility." } } }, "auth_ref": [] }, "us-gaap_AccrualForEnvironmentalLossContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccrualForEnvironmentalLossContingencies", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Accrual for Environmental Loss Contingencies", "terseLabel": "Accrual for Environmental Loss Contingencies", "documentation": "Total costs accrued as of the balance sheet date for environmental loss contingencies." } } }, "auth_ref": [ "r418", "r1125", "r1347", "r1348", "r1490", "r1493" ] }, "teva_AccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AccruedExpenses", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued Expenses", "terseLabel": "Accrued expenses", "documentation": "Accrued expenses." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" ], "lang": { "en-us": { "role": { "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Benefit Plans [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r4", "r5", "r16", "r24", "r81", "r1381", "r1382", "r1383" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" ], "lang": { "en-us": { "role": { "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Derivative Financial Instruments [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r170", "r178", "r179", "r656", "r731", "r732", "r733", "r734", "r1098", "r1381" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r177", "r178", "r731", "r732", "r733", "r734", "r784", "r786", "r787", "r788", "r789", "r790" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 34.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r23", "r24", "r82", "r160", "r900", "r946", "r950", "r1568" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r16", "r24", "r725", "r728", "r806", "r941", "r942", "r1381", "r1382", "r1383", "r1438", "r1439", "r1440", "r1441" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" ], "lang": { "en-us": { "role": { "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation Adjustments [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r3", "r16", "r24", "r79", "r80", "r178", "r179", "r786", "r787", "r788", "r789", "r790", "r1381" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r1296" ] }, "teva_AdditionalDevelopmentAndMilestonePaymentsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AdditionalDevelopmentAndMilestonePaymentsReceivable", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Additional Development And Milestone Payments Receivable", "terseLabel": "Additional development and milestone payments receivable", "documentation": "Additional development and milestone payments receivable." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 32.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "verboseLabel": "Additional\u00a0paid-in\u00a0capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r71", "r1224", "r1647" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r965", "r1438", "r1439", "r1440", "r1441", "r1569", "r1649" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r1309" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r1309" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r1309" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r1309" ] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentForAmortization", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Amortization", "terseLabel": "Amortization", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": [ "r12" ] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": [ "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r193", "r194", "r195", "r220", "r221", "r222", "r223", "r224", "r234", "r297", "r298", "r333", "r334", "r335", "r336", "r388", "r389", "r404", "r464", "r465", "r466", "r467", "r549", "r550", "r551", "r552", "r569", "r570", "r571", "r572", "r573", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r625", "r626", "r627", "r645", "r646", "r647", "r648", "r649", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r771", "r772", "r794", "r795", "r801", "r802", "r803", "r804", "r805", "r806", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r520" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operations:" } } }, "auth_ref": [] }, "teva_AggregateUpfrontAndMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AggregateUpfrontAndMilestonePayments", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Aggregate Upfront And Milestone Payments", "terseLabel": "Aggregate upfront and milestone payments", "documentation": "Aggregate Upfront And Milestone Payments." } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r1342" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1268", "r1278", "r1288", "r1320" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r1271", "r1281", "r1291", "r1323" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r1343" ] }, "teva_AgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AgreementAxis", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Agreement [Axis]", "documentation": "Agreement." } } }, "auth_ref": [] }, "teva_AgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AgreementDomain", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Agreement [Domain]", "documentation": "Agreement." } } }, "auth_ref": [] }, "teva_AgreementMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AgreementMilestonePayments", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Agreement Milestone Payments", "terseLabel": "Agreement Milestone Payments", "documentation": "Agreement milestone payments." } } }, "auth_ref": [] }, "teva_AjovyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AjovyMember", "presentation": [ "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "AJOVY [Member]" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r1309" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "AllCurrenciesDomain", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r1316" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r1272", "r1282", "r1292", "r1316", "r1324", "r1328", "r1336" ] }, "us-gaap_AllOtherSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AllOtherSegmentsMember", "presentation": [ "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Other Segments [Member]", "terseLabel": "Other Segments [Member]", "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": [ "r263", "r283", "r284", "r285", "r286", "r287", "r290", "r1115", "r1116" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r1334" ] }, "teva_AllerganTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AllerganTransactionMember", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" ], "lang": { "en-us": { "role": { "label": "Allergan transaction [Member]" } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss, Current", "verboseLabel": "Allowance for credit losses", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r161", "r300", "r337" ] }, "teva_AlvotechMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AlvotechMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Alvotech [Member]", "documentation": "Alvotech." } } }, "auth_ref": [] }, "teva_AmendedRevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AmendedRevolvingCreditFacilityMember", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Amended Revolving Credit Facility [Member]", "documentation": "Amended revolving credit facility member." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets." } } }, "auth_ref": [ "r12", "r192", "r373", "r380", "r1086", "r1099", "r1101", "r1103", "r1105" ] }, "teva_AmountsAllocatedToSegmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AmountsAllocatedToSegmentsAbstract", "presentation": [ "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Amounts Allocated To Segments [Abstract]", "documentation": "Amounts allocated to segments." } } }, "auth_ref": [] }, "teva_AmountsNotAllocatedToSegmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AmountsNotAllocatedToSegmentsAbstract", "presentation": [ "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Amounts Not Allocated To Segments [Abstract]", "documentation": "Amounts not allocated to segments." } } }, "auth_ref": [] }, "teva_AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AnnualSalesAtTheTimeOfNuvigilEnteredIntoFirstSettlementOfWithAnAndaFiler", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales At The Time Of Nuvigil Entered Into First Settlement Of With AN ANDA Filer", "terseLabel": "Annual Sales At The Time Of Nuvigil Entered Into First Settlement Of With AN ANDA Filer", "documentation": "Annual sales at The time of nuvigil entered into first settlement of with AN ANDA hiler." } } }, "auth_ref": [] }, "teva_AnnualSalesOfEffexor": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AnnualSalesOfEffexor", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales Of Effexor", "terseLabel": "Annual sales of Effexor", "documentation": "Annual sales of effexor." } } }, "auth_ref": [] }, "teva_AnnualSalesOfLamictal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AnnualSalesOfLamictal", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales Of Lamictal", "terseLabel": "Annual sales of Lamictal", "documentation": "Annual sales of Lamictal." } } }, "auth_ref": [] }, "teva_AnnualSalesOfNiaspan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AnnualSalesOfNiaspan", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales Of Niaspan", "terseLabel": "Annual sales of Niaspan", "documentation": "Annual sales of Niaspan." } } }, "auth_ref": [] }, "teva_AnnualSalesOfRevlimid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AnnualSalesOfRevlimid", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales Of Revlimid", "terseLabel": "Annual Sales Of Revlimid", "documentation": "Annual sales of revlimid." } } }, "auth_ref": [] }, "teva_AnnualSalesOfTheTimeOfNewLaunchOfAtripla": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AnnualSalesOfTheTimeOfNewLaunchOfAtripla", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales Of The Time Of New Launch Of Atripla", "terseLabel": "Annual sales of the time of New launch of Atripla", "documentation": "Annual sales of the time of new launch of Atripla." } } }, "auth_ref": [] }, "teva_AnnualSalesOfTheTimeOfNewLaunchOfTruvada": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AnnualSalesOfTheTimeOfNewLaunchOfTruvada", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales Of The Time Of New Launch Of Truvada", "terseLabel": "Annual sales of the time of New launch of Truvada", "documentation": "Annual sales of the time of New launch of truvada." } } }, "auth_ref": [] }, "teva_AnnualSalesOfTheTimeOfSettlementOfAtripla": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AnnualSalesOfTheTimeOfSettlementOfAtripla", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales Of The Time Of Settlement Of Atripla", "terseLabel": "Annual sales of the time of settlement of Atripla", "documentation": "Annual sales of the time of settlement of atripla." } } }, "auth_ref": [] }, "teva_AnnualSalesOfTheTimeOfSettlementOfTruvada": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AnnualSalesOfTheTimeOfSettlementOfTruvada", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales Of The Time Of Settlement Of Truvada", "terseLabel": "Annual sales of the time of settlement of Truvada", "documentation": "Annual sales of the time of settlement of truvada." } } }, "auth_ref": [] }, "teva_AnnualSalesOfXifaxan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AnnualSalesOfXifaxan", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Annual Sales Of Xifaxan", "terseLabel": "Annual sales of Xifaxan", "documentation": "Annual Sales Of Xifaxan" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail", "http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Diluted effect of stock options, RSUs and PSUs", "terseLabel": "Weighted average shares with anti-dilutive effect on earnings per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r251" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r251" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r251" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r251" ] }, "us-gaap_AociTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AociTaxAttributableToParent", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" ], "lang": { "en-us": { "role": { "label": "AOCI Tax, Attributable to Parent", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "documentation": "Amount of tax expense (benefit) allocated to accumulated other comprehensive income (loss) attributable to parent." } } }, "auth_ref": [] }, "teva_ApplicabilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ApplicabilityAxis", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Applicability [Axis]", "documentation": "Applicability." } } }, "auth_ref": [] }, "teva_ApplicabilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ApplicabilityDomain", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Applicability [Domain]", "documentation": "Applicability." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r650" ] }, "us-gaap_AssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "teva_AssetAcquisitionAcquiredIprAndD": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AssetAcquisitionAcquiredIprAndD", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsSummaryOfAssetsAcquiredLiabilitiesAssumedDetail" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition Acquired IPR and D", "verboseLabel": "Acquired IPR&D", "documentation": "Asset acquisition acquired ipr and d." } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsSummaryOfAssetsAcquiredLiabilitiesAssumedDetail" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r366", "r374", "r375", "r376", "r377", "r378", "r953", "r1547" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsSummaryOfAssetsAcquiredLiabilitiesAssumedDetail" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred", "verboseLabel": "Total consideration allocated", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r1188", "r1548", "r1549", "r1550" ] }, "teva_AssetAcquisitionConsiderationTransferredAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AssetAcquisitionConsiderationTransferredAccruedExpenses", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsSummaryOfAssetsAcquiredLiabilitiesAssumedDetail" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition Consideration Transferred Accrued Expenses", "verboseLabel": "Accrued expenses", "documentation": "Asset acquisition consideration transferred accrued expenses." } } }, "auth_ref": [] }, "teva_AssetAcquisitionConsiderationTransferredCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AssetAcquisitionConsiderationTransferredCash", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsSummaryOfAssetsAcquiredLiabilitiesAssumedDetail" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition Consideration Transferred Cash", "verboseLabel": "Cash consideration for outstanding shares, net of working capital adjustments", "documentation": "Asset acquisition consideration transferred cash." } } }, "auth_ref": [] }, "teva_AssetAcquisitionConsiderationTransferredDeferredIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AssetAcquisitionConsiderationTransferredDeferredIncomeTaxes", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsSummaryOfAssetsAcquiredLiabilitiesAssumedDetail" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition Consideration Transferred Deferred Income Taxes", "verboseLabel": "Deferred income taxes", "documentation": "Asset acquisition consideration transferred deferred income taxes." } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionConsiderationTransferredOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetAcquisitionConsiderationTransferredOtherAssets", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsSummaryOfAssetsAcquiredLiabilitiesAssumedDetail" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred, Other Assets", "verboseLabel": "Other current assets", "documentation": "Amount of tangible and intangible assets included as part of consideration transferred in asset acquisition, classified as other. Excludes cash." } } }, "auth_ref": [ "r1548", "r1549", "r1550" ] }, "teva_AssetAcquisitionConsiderationTransferredOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AssetAcquisitionConsiderationTransferredOtherLiabilities", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsSummaryOfAssetsAcquiredLiabilitiesAssumedDetail" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition Consideration Transferred Other Liabilities", "verboseLabel": "Other liabilities", "documentation": "Asset acquisition consideration transferred other liabilities." } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsSummaryOfAssetsAcquiredLiabilitiesAssumedDetail" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred, Transaction Cost", "verboseLabel": "Transaction costs", "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r1188", "r1548", "r1549", "r1550" ] }, "teva_AssetAcquisitionConsiderationTransferredValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AssetAcquisitionConsiderationTransferredValuationAllowance", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsSummaryOfAssetsAcquiredLiabilitiesAssumedDetail" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition Consideration Transferred Valuation Allowance", "verboseLabel": "Valuation allowance", "documentation": "Asset acquisition consideration transferred valuation allowance." } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsSummaryOfAssetsAcquiredLiabilitiesAssumedDetail" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r366", "r374", "r375", "r376", "r377", "r378", "r953", "r1547" ] }, "teva_AssetAcquisitionIdentifiableAssetsAndLiabilitiesAcquiredNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AssetAcquisitionIdentifiableAssetsAndLiabilitiesAcquiredNet", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsSummaryOfAssetsAcquiredLiabilitiesAssumedDetail" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition Identifiable Assets And Liabilities Acquired Net", "verboseLabel": "Total identifiable assets and liabilities acquired", "documentation": "Asset acquisition identifiable assets and liabilities acquired net." } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetAcquisitionLineItems", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsSummaryOfAssetsAcquiredLiabilitiesAssumedDetail" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r366", "r1547" ] }, "us-gaap_AssetAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetAcquisitionTable", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsSummaryOfAssetsAcquiredLiabilitiesAssumedDetail" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Table]", "documentation": "Disclosure of information about asset acquisition." } } }, "auth_ref": [ "r366", "r1547" ] }, "us-gaap_AssetAcquisitionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetAcquisitionTableTextBlock", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsTables" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Table Text Block]", "verboseLabel": "Summary of Assets Acquired, liabilities Assumed", "documentation": "Tabular disclosure of asset acquisition." } } }, "auth_ref": [ "r1547" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r115", "r125", "r154", "r200", "r205", "r206", "r255", "r266", "r285", "r289", "r332", "r425", "r426", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r652", "r657", "r778", "r889", "r890", "r898", "r1008", "r1115", "r1116", "r1136", "r1224", "r1241", "r1242", "r1259", "r1501", "r1502", "r1598" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsAbstract", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r148", "r165", "r200", "r205", "r206", "r332", "r425", "r426", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r652", "r657", "r778", "r1224", "r1501", "r1502", "r1598" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsFairValueAdjustment", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Adjustment", "verboseLabel": "Expected loss on sale", "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties." } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail", "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel": "Assets held for sale", "verboseLabel": "Total assets of the disposal group classified as held for sale in the consolidated balance sheets", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r55", "r57", "r97", "r99", "r146", "r147" ] }, "teva_AustedoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "AustedoMember", "presentation": [ "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "Austedo [Member]", "terseLabel": "AUSTEDO [Member]", "documentation": "Austedo [Member]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r1331" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r1332" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r1327" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r1327" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r1327" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r1327" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r1327" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r1327" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r543", "r544", "r545", "r546", "r547" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r1330" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1329" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r1328" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r1328" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance is reported." } } }, "auth_ref": [ "r398", "r670", "r674", "r675", "r676", "r677", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r777", "r1205", "r1206", "r1358", "r1610" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance is reported." } } }, "auth_ref": [ "r398", "r670", "r674", "r675", "r676", "r677", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r777", "r1205", "r1206", "r1358", "r1610" ] }, "teva_BasisOfPresentationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "BasisOfPresentationAbstract", "lang": { "en-us": { "role": { "label": "Basis of Presentation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.tevapharm.com/role/BasisOfPresentation" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "verboseLabel": "Basis of presentation", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r1429" ] }, "teva_BasisOfPresentationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "BasisOfPresentationTable", "presentation": [ "http://www.tevapharm.com/role/BasisOfPresentation" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation [Table]" } } }, "auth_ref": [] }, "teva_BendekaAndTreandaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "BendekaAndTreandaMember", "presentation": [ "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "BENDEKA and TREANDA [Member]", "verboseLabel": "BENDEKA and TREANDA [Member]", "documentation": "BENDEKA and TREANDA." } } }, "auth_ref": [] }, "teva_BeneficialInterestObtainedInExchangeForSecuritizedAccountsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "BeneficialInterestObtainedInExchangeForSecuritizedAccountsReceivables", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Beneficial Interest Obtained in Exchange for Securitized Accounts Receivables", "verboseLabel": "Beneficial interest obtained in exchange for securitized accounts receivables", "documentation": "Beneficial interest obtained in exchange for securitized accounts receivables." } } }, "auth_ref": [] }, "teva_BiolojicDesignLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "BiolojicDesignLtdMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Biolojic Design Ltd [Member]", "terseLabel": "Biolojic Design Ltd [Member]", "documentation": "Biolojic design ltd." } } }, "auth_ref": [] }, "teva_BlackstoneLifeSciencesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "BlackstoneLifeSciencesMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Blackstone Life Sciences [Member]", "terseLabel": "Blackstone Life Sciences [Member]" } } }, "auth_ref": [] }, "teva_BrianPSavageInterimChiefLegalOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "BrianPSavageInterimChiefLegalOfficerMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Brian P. Savage, Interim Chief Legal Officer [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]", "documentation": "Business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r366", "r374", "r375", "r376", "r377", "r378", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r953", "r1151", "r1152", "r1542", "r1544", "r1545" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination [Axis]", "terseLabel": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r366", "r374", "r375", "r376", "r377", "r378", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r953", "r1151", "r1152", "r1542", "r1544", "r1545" ] }, "us-gaap_BusinessCombinationConsiderationTransferredAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessCombinationConsiderationTransferredAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Consideration Transferred [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": { "parentTag": "teva_ImpairmentAndRestructuring", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "definitionGuidance": "Contingent consideration", "verboseLabel": "Business combination contingent consideration arrangements change in amount of contingent consideration liability", "documentation": "Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement." } } }, "auth_ref": [ "r642", "r1428" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration, Liability", "negatedLabel": "Contingent consideration", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r634", "r641", "r751", "r752", "r753", "r1155", "r1158" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Business combination, contingent consideration, liability, measurement input", "documentation": "Value of input used to measure liability in contingent consideration arrangement in business combination." } } }, "auth_ref": [ "r635", "r641", "r751", "r752", "r753", "r1155", "r1158" ] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "teva_COPAXONEMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "COPAXONEMember", "presentation": [ "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "COPAXONE [Member]", "terseLabel": "COPAXONE [Member]", "documentation": "COPAXONE." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r28", "r150", "r1087" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r773", "r774", "r775", "r1571", "r1572" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodStartLabel": "Balance of cash and cash equivalents at beginning of period", "periodEndLabel": "Balance of cash and cash equivalents at end of period", "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r28", "r92", "r199" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r0", "r92" ] }, "teva_CertainTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "CertainTransactionsDisclosureTextBlock", "presentation": [ "http://www.tevapharm.com/role/CertainTransactions" ], "lang": { "en-us": { "role": { "label": "Certain Transactions Disclosure [Text Block]", "terseLabel": "Certain transactions", "documentation": "This element may be used for the entire related party transactions disclosure as a single block of text. Disclosure may include: business acquisitions, agreements with related parties, significant cooperation agreements, the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [] }, "teva_CertainTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "CertainTransactionsTable", "presentation": [ "http://www.tevapharm.com/role/CertainTransactions", "http://www.tevapharm.com/role/CertainTransactionsTables" ], "lang": { "en-us": { "role": { "label": "Certain Transactions [Table]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r1307" ] }, "teva_ChargebacksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ChargebacksMember", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "Chargebacks [Member]", "terseLabel": "Chargebacks [Member]", "documentation": "Chargebacks." } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r1304" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r1302" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "teva_CivilActionInRespectOfDonationsToPatientAssistanceProgrammersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "CivilActionInRespectOfDonationsToPatientAssistanceProgrammersMember", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Civil Action In Respect Of Donations To Patient Assistance Programmers [Member]", "terseLabel": "Civil Action In Respect Of Donations To Patient Assistance Programmers [Member]", "documentation": "Civil action in respect of donations to patient assistance programmers." } } }, "auth_ref": [] }, "teva_CivilInvestigativeDemandFromDepartmentOfJusticeCivilDivisionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "CivilInvestigativeDemandFromDepartmentOfJusticeCivilDivisionMember", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Civil Investigative Demand From Department Of Justice Civil Division [Member]", "terseLabel": "Civil Investigative Demand From Department Of Justice Civil Division [Member]", "documentation": "Civil investigative demand from department of justice civil division." } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfStockDomain", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r131", "r157", "r158", "r159", "r200", "r206", "r238", "r239", "r248", "r250", "r257", "r258", "r332", "r425", "r428", "r429", "r430", "r434", "r435", "r468", "r469", "r471", "r472", "r474", "r476", "r479", "r480", "r483", "r486", "r493", "r778", "r957", "r958", "r959", "r960", "r965", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r996", "r1016", "r1034", "r1056", "r1057", "r1058", "r1059", "r1060", "r1346", "r1432", "r1434", "r1442" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r1308" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r1308" ] }, "teva_CollaborationPartnerFundingReimbursements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "CollaborationPartnerFundingReimbursements", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Collaboration Partner Funding Reimbursements", "verboseLabel": "Collaboration partner funding reimbursements", "documentation": "Collaboration partner funding reimbursements." } } }, "auth_ref": [] }, "teva_CollaborativeAgreementMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "CollaborativeAgreementMilestonePayments", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Collaborative Agreement Milestone Payments", "terseLabel": "Collaborative agreement milestone payments", "documentation": "Collaborative Agreement Milestone Payments" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CollaborativeArrangementMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement [Member]", "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity." } } }, "auth_ref": [ "r650" ] }, "teva_CommissionSuretyUnderwrittenGuarantees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "CommissionSuretyUnderwrittenGuarantees", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Commission Surety Underwritten Guarantees", "terseLabel": "Commission surety underwritten guarantees", "documentation": "Commission Surety Underwritten Guarantees" } } }, "auth_ref": [] }, "teva_CommitmentAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "CommitmentAndContingenciesLineItems", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Commitment And Contingencies [Line Items]", "terseLabel": "Commitment And Contingencies [Line Items]", "documentation": "Commitment And Contingencies [Line Items]" } } }, "auth_ref": [] }, "teva_CommitmentAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "CommitmentAndContingenciesTable", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Commitment And Contingencies [Table]", "terseLabel": "Commitment And Contingencies [Table]", "documentation": "Commitment And Contingencies [Table]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r103", "r413", "r414", "r1069", "r1485", "r1492" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockMember", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Ordinary Shares [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r1244", "r1245", "r1246", "r1248", "r1249", "r1250", "r1253", "r1438", "r1439", "r1441", "r1569", "r1645", "r1649" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par or stated value per share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r70" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Ordinary shares, authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r70", "r996" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Ordinary shares, issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r70" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 31.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Ordinary shares of NIS 0.10 par value per share; June\u00a030, 2026 and December\u00a031, 2025: authorized 2,495\u00a0million shares; issued 1,271\u00a0million shares and 1,257\u00a0million shares, respectively.", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r70", "r469", "r475", "r899", "r1224" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r1313" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r1312" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r1314" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r1311" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss) attributable to Teva", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r25", "r174", "r176", "r183", "r887", "r911", "r913" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive income (loss) attributable to redeemable and non-redeemable non-controlling interests", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r10", "r50", "r53", "r174", "r176", "r182", "r886", "r911", "r912" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total comprehensive income (loss)", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r53", "r112", "r174", "r176", "r181", "r885", "r911" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r259", "r296", "r954", "r955", "r1068", "r1445", "r1446", "r1447", "r1448", "r1449" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r259", "r296", "r954", "r955", "r1068", "r1445", "r1446", "r1447", "r1448", "r1449" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r259", "r296", "r954", "r955", "r1068", "r1445", "r1446", "r1447", "r1448", "r1449" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r259", "r296", "r954", "r955", "r1068", "r1445", "r1446", "r1447", "r1448", "r1449" ] }, "teva_ConsiderationArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ConsiderationArrangementAxis", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Consideration Arrangement [Axis]" } } }, "auth_ref": [] }, "teva_ConsiderationArrangementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ConsiderationArrangementDomain", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Consideration Arrangement [Domain]" } } }, "auth_ref": [] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r123", "r200", "r201", "r208", "r211", "r255", "r268", "r283", "r284", "r285", "r286", "r287", "r289", "r290", "r291", "r425", "r426", "r427", "r428", "r430", "r431", "r432", "r433", "r434", "r893", "r1115", "r1116", "r1501", "r1502" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r123", "r200", "r201", "r208", "r211", "r255", "r268", "r283", "r284", "r285", "r286", "r287", "r289", "r290", "r291", "r425", "r426", "r427", "r428", "r430", "r431", "r432", "r433", "r434", "r893", "r1115", "r1116", "r1501", "r1502" ] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConvertibleDebtMember", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r106", "r437", "r438", "r448", "r449", "r450", "r454", "r455", "r456", "r457", "r458", "r1131", "r1132", "r1133", "r1134", "r1135" ] }, "us-gaap_ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ConvertiblePreferredStockMember", "presentation": [ "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock [Member]", "terseLabel": "Convertible Preferred Stock [Member]", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option." } } }, "auth_ref": [ "r479", "r480", "r483", "r1248", "r1249", "r1250", "r1253" ] }, "us-gaap_CorporateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CorporateMember", "presentation": [ "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Corporate Segment [Member]", "terseLabel": "Corporate Segment [Member]", "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": [ "r1450" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r85", "r86", "r845", "r1101", "r1106", "r1195", "r1421" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CostOfRevenue", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Cost of Revenue", "terseLabel": "Cost of Sales", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r87", "r200", "r205", "r206", "r332", "r425", "r426", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r778", "r1115", "r1501" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r200", "r209", "r210", "r440", "r481", "r807", "r828", "r897", "r1094", "r1096", "r1097", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1563", "r1564", "r1565", "r1566" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CreditFacilityAxis", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r423", "r1498" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CreditFacilityDomain", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r423", "r1498" ] }, "us-gaap_CrossCurrencyInterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "CrossCurrencyInterestRateContractMember", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Cross Currency Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates." } } }, "auth_ref": [ "r517", "r1508", "r1509", "r1557", "r1558", "r1559", "r1560" ] }, "teva_CrossCurrencySwapCashFlowHedgeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "CrossCurrencySwapCashFlowHedgeMember", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Cross Currency Swap Cash Flow Hedge [Member]", "documentation": "Cross Currency Swap Cash Flow Hedge." } } }, "auth_ref": [] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CurrencyAxis", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "auth_ref": [ "r1593" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtCurrent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "Debt, Current", "terseLabel": "Short-term debt", "verboseLabel": "Total short term debt", "documentation": "Amount of debt and lease obligation, classified as current." } } }, "auth_ref": [ "r156" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.tevapharm.com/role/DebtObligations" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt obligations", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r105", "r200", "r204", "r393", "r394", "r395", "r396", "r397", "r422", "r423", "r436", "r442", "r443", "r444", "r445", "r446", "r447", "r452", "r459", "r460", "r462", "r719", "r792" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtParentheticalDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r21", "r60", "r61", "r116", "r117", "r437", "r438", "r439", "r440", "r441", "r443", "r448", "r449", "r450", "r451", "r453", "r454", "r455", "r456", "r457", "r458", "r1131", "r1132", "r1133", "r1134", "r1135", "r1223", "r1430", "r1431", "r1433", "r1437", "r1486", "r1487", "r1488", "r1595", "r1596", "r1606" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Debt instrument face amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r437", "r792", "r793", "r1132", "r1133", "r1223" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Total", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r450", "r773", "r774", "r775", "r776", "r1132", "r1133", "r1572", "r1573", "r1574", "r1575", "r1582" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "definitionGuidance": "Weighted\u00a0average interest rate", "terseLabel": "Weighted average interest rate", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r63", "r463", "r792", "r793", "r1223" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r437", "r438", "r439", "r440", "r441", "r443", "r448", "r449", "r450", "r451", "r453", "r454", "r455", "r456", "r457", "r458", "r461", "r719", "r893", "r1131", "r1132", "r1133", "r1134", "r1135", "r1223", "r1430", "r1431", "r1433", "r1437", "r1595", "r1596" ] }, "teva_DebtInstrumentMaturityYear": { "xbrltype": "gYearItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "DebtInstrumentMaturityYear", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Maturity Year", "terseLabel": "Maturity", "documentation": "Debt Instrument Maturity Year" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtParentheticalDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r21", "r437", "r438", "r439", "r440", "r441", "r443", "r448", "r449", "r450", "r451", "r453", "r454", "r455", "r456", "r457", "r458", "r1131", "r1132", "r1133", "r1134", "r1135", "r1223", "r1430", "r1431", "r1433", "r1437", "r1486", "r1487", "r1488", "r1595", "r1596", "r1606" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtInstrumentTable", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r21", "r43", "r44", "r54", "r108", "r109", "r437", "r438", "r439", "r440", "r441", "r443", "r448", "r449", "r450", "r451", "r453", "r454", "r455", "r456", "r457", "r458", "r461", "r719", "r893", "r1131", "r1132", "r1133", "r1134", "r1135", "r1223", "r1430", "r1431", "r1433", "r1437", "r1595", "r1596" ] }, "teva_DebtObligationsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "DebtObligationsTable", "presentation": [ "http://www.tevapharm.com/role/DebtObligations", "http://www.tevapharm.com/role/DebtObligationsTables" ], "lang": { "en-us": { "role": { "label": "Debt Obligations [Table]" } } }, "auth_ref": [] }, "us-gaap_DebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DebtWeightedAverageInterestRate", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt, Weighted Average Interest Rate", "terseLabel": "Debt, weighted average interest rate", "documentation": "Weighted average interest rate of debt outstanding." } } }, "auth_ref": [] }, "teva_DefendantsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "DefendantsAxis", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Defendants [Axis]", "documentation": "Defendants." } } }, "auth_ref": [] }, "teva_DefendantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "DefendantsMember", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Defendants [Member]", "documentation": "Defendants." } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsNoncurrentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredFinanceCostsNoncurrentNet", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail" ], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs, Noncurrent, Net", "negatedLabel": "Less debt issuance costs", "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1594", "r1595", "r1596" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred income taxes", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r558", "r559" ] }, "teva_DeferredIncomeTaxesNetAndUncertainTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "DeferredIncomeTaxesNetAndUncertainTaxPositions", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 23.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deferred Income Taxes Net And Uncertain Tax Positions", "verboseLabel": "Deferred income taxes \u2013 net and uncertain tax positions", "documentation": "Deferred income taxes net and uncertain tax positions." } } }, "auth_ref": [] }, "teva_DeferredProsecutionAgreementWithU.s.DepartmentOfJusticeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "DeferredProsecutionAgreementWithU.s.DepartmentOfJusticeMember", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Prosecution Agreement With U.S. Department of Justice [Member]", "documentation": "Deferred prosecution agreement with U.S. department of justice." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 24.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred Tax and Other Liabilities, Noncurrent", "terseLabel": "Deferred income taxes", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other." } } }, "auth_ref": [] }, "us-gaap_DemandDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DemandDepositsMember", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Demand Deposits [Member]", "terseLabel": "Cash, Deposits and Other [Member]", "documentation": "Accounts that may or may not bear interest and that depositor is entitled to withdraw at anytime without prior notice. Checking and negotiable order of withdrawal (NOW) accounts are the most common forms of demand deposits." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/SegmentsParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r12", "r39", "r191", "r1099", "r1101", "r1103", "r1105" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 21.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r12", "r39" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeAssets", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Asset", "verboseLabel": "Derivatives", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r167", "r168", "r718", "r749", "r750", "r763", "r773", "r774", "r775", "r978", "r979", "r980", "r981", "r982", "r984", "r985", "r986", "r987", "r988", "r1002", "r1003", "r1046", "r1049", "r1050", "r1051", "r1052", "r1053", "r1083", "r1093", "r1095", "r1096", "r1097", "r1210", "r1215", "r1222", "r1246", "r1573", "r1574", "r1575", "r1646" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r189", "r670", "r671", "r672", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r986", "r988", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1009", "r1010", "r1011", "r1012", "r1022", "r1023", "r1024", "r1025", "r1028", "r1029", "r1030", "r1031", "r1046", "r1047", "r1050", "r1052", "r1093", "r1094", "r1097", "r1205", "r1206", "r1244", "r1246", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1563", "r1564", "r1565", "r1566", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581", "r1583", "r1584" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Asset derivatives", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r19", "r166", "r718", "r1093", "r1095", "r1096", "r1097" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Liability, Fair Value, Gross Liability", "negatedLabel": "Liability derivatives", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r19", "r166", "r718", "r1093", "r1095", "r1096", "r1097" ] }, "us-gaap_DerivativeInstrumentDetailAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeInstrumentDetailAbstract", "lang": { "en-us": { "role": { "label": "Derivative Instrument Detail [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r189", "r670", "r671", "r672", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r986", "r988", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1009", "r1010", "r1011", "r1012", "r1022", "r1023", "r1024", "r1025", "r1028", "r1029", "r1030", "r1031", "r1046", "r1047", "r1050", "r1052", "r1093", "r1094", "r1097", "r1205", "r1206", "r1244", "r1246", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1563", "r1564", "r1565", "r1566", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581", "r1583", "r1584" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivities" ], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Instruments and Hedging Activities", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r720", "r735", "r1205", "r1206", "r1207", "r1208", "r1209" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Liability", "negatedLabel": "Derivatives", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r167", "r168", "r718", "r749", "r750", "r763", "r773", "r774", "r775", "r978", "r979", "r980", "r981", "r984", "r985", "r986", "r987", "r988", "r1009", "r1011", "r1012", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1093", "r1095", "r1096", "r1097", "r1573", "r1574", "r1575", "r1646" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeLineItems", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r735", "r1567" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative, Notional Amount", "verboseLabel": "Derivative notional amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1205", "r1551", "r1552" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeTable", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Derivative [Table]", "terseLabel": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": [ "r735", "r1567" ] }, "us-gaap_DerivativeTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DerivativeTermOfContract", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative, Term of Contract", "terseLabel": "Derivatives term of contract", "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail" ], "lang": { "en-us": { "role": { "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [] }, "teva_DevelopmentAndLaunchMilestonePaymentReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "DevelopmentAndLaunchMilestonePaymentReceivable", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Development and Launch Milestone Payment Receivable", "terseLabel": "Development and launch milestone payment receivable", "documentation": "Development and launch milestone payment receivable." } } }, "auth_ref": [] }, "teva_DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "DevelopmentProgressAndChangesInOtherKeyValuationAssumptionsMember", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Development Progress And Changes In Other Key Valuation Assumptions [Member]", "terseLabel": "Development Progress And Changes In Other Key Valuation Assumptions [Member]", "documentation": "Development progress and changes in other key valuation assumptions." } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisaggregationOfRevenueAbstract", "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r504", "r505", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r504", "r505", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Summary of disaggregates revenues by major revenue streams", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1506" ] }, "teva_DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "DisclosureInTabularFormOfPretaxGainLossCashFlowHedgingInstrumentsTableTextBlock", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure In Tabular Form Of Pretax Gain Loss Cash Flow Hedging Instruments [Table Text Block]", "terseLabel": "Summary of Pre-tax (Gains) Losses From Derivatives Designated in Cash Flow Hedging Relationships", "documentation": "Disclosure in tabular form of pretax gain loss cash flow hedging instruments." } } }, "auth_ref": [] }, "teva_DiscontinuationOfBusinessAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "DiscontinuationOfBusinessAxis", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Discontinuation Of Business [Axis]" } } }, "auth_ref": [] }, "teva_DiscontinuationOfBusinessDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "DiscontinuationOfBusinessDomain", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Discontinuation Of Business [Domain]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "terseLabel": "Accounts receivables", "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r55", "r57", "r99" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayable", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Accounts Payable", "negatedLabel": "Accounts payables", "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r55", "r57", "r99" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Goodwill, Current", "terseLabel": "Goodwill", "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r55", "r57", "r97", "r99" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Current", "terseLabel": "Identifiable intangible assets, net", "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r55", "r57", "r97", "r99" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Inventory, Current", "terseLabel": "Inventories", "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r55", "r57", "r97", "r99" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current", "terseLabel": "Other current assets", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r55", "r57", "r97", "r99" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent", "terseLabel": "Other non-current assets", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r6", "r55", "r57", "r99" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current", "terseLabel": "Property, plant and equipment, net", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r55", "r57", "r97", "r99" ] }, "us-gaap_DistributionServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DistributionServiceMember", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" ], "lang": { "en-us": { "role": { "label": "Distribution Service [Member]", "terseLabel": "Distribution [Member]", "documentation": "Distribution assistance, including, but not limited to, marketing and selling fund shares, advertising, printing and mailing of prospectus and sale literature to investor." } } }, "auth_ref": [ "r1506", "r1507" ] }, "us-gaap_DividendsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DividendsAxis", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Dividends [Axis]", "documentation": "Information by event wherein earnings are distributed to shareholder." } } }, "auth_ref": [ "r1504", "r1505" ] }, "us-gaap_DividendsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "DividendsDomain", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Dividends [Domain]", "documentation": "Event wherein earnings are distributed to shareholder." } } }, "auth_ref": [ "r1504", "r1505" ] }, "teva_DividendsPaidToNonControllingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "DividendsPaidToNonControllingInterests", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Dividends Paid To Non controlling Interests", "terseLabel": "Dividends paid to redeemable and non-redeemable non-controlling interests", "documentation": "Dividends paid to noncontrolling interests." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r1263" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r1295" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "teva_DonationOfClotrimazoleAndTobramycinMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "DonationOfClotrimazoleAndTobramycinMember", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Donation of Clotrimazole and Tobramycin [Member]", "documentation": "Donation of clotrimazole and tobramycin." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r1306" ] }, "teva_EagleTransactionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "EagleTransactionMember", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" ], "lang": { "en-us": { "role": { "label": "Eagle Transaction [Member]", "terseLabel": "Eagle Transaction [Member]", "documentation": "Eagle transaction." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings (loss) per share attributable to ordinary shareholders:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Basic", "verboseLabel": "Basic earnings (loss) attributable to Teva's ordinary shareholders", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r142", "r184", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r236", "r238", "r248", "r249", "r250", "r254", "r467", "r551", "r587", "r649", "r746", "r747", "r888", "r914", "r1107" ] }, "us-gaap_EarningsPerShareBasicLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareBasicLineItems", "presentation": [ "http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r238", "r239", "r248", "r250" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted", "verboseLabel": "Diluted earnings (loss) attributable to Teva's ordinary shareholders", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r142", "r184", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r238", "r248", "r249", "r250", "r254", "r467", "r551", "r587", "r649", "r746", "r747", "r888", "r914", "r1107" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.tevapharm.com/role/EarningsLossPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings (Loss) per share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r235", "r251", "r252", "r253" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 29.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r782" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory tax rate in Israel", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r200", "r207", "r561", "r574", "r1154" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsOther": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsOther", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Other, Percent", "terseLabel": "Effective income tax rate reconciliation, tax settlement, other, percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other income tax settlements." } } }, "auth_ref": [ "r1430", "r1436", "r1537", "r1538" ] }, "teva_EmalexBiosciencesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "EmalexBiosciencesMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/CertainTransactionsSummaryOfAssetsAcquiredLiabilitiesAssumedDetail" ], "lang": { "en-us": { "role": { "label": "Emalex Biosciences [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Employee-related obligations", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r61" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "Employee Severance [Member]", "terseLabel": "Employee termination [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [ "r1510", "r1511", "r1512", "r1513", "r1514", "r1515", "r1516", "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534", "r1535" ] }, "teva_EmployeeTerminationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "EmployeeTerminationMember", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "label": "Employee Termination [Member]", "terseLabel": "Employee termination costs [Member]", "documentation": "Employee termination." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "terseLabel": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1261" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityDomain", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail", "http://www.tevapharm.com/role/CertainTransactions", "http://www.tevapharm.com/role/CertainTransactionsTables", "http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows", "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/DebtObligations", "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtParentheticalDetail", "http://www.tevapharm.com/role/DebtObligationsTables", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail", "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail", "http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail", "http://www.tevapharm.com/role/FairValueMeasurement", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail", "http://www.tevapharm.com/role/FairValueMeasurementTables", "http://www.tevapharm.com/role/Goodwill", "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail", "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail", "http://www.tevapharm.com/role/GoodwillTables", "http://www.tevapharm.com/role/IdentifiableIntangibleAssets", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables", "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.tevapharm.com/role/Inventories", "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail", "http://www.tevapharm.com/role/InventoriesTables", "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables", "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail", "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "terseLabel": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1261" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r1261" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r1345" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1261" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r1261" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitySmallBusiness", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Smaller Reporting Company", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r1261" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1261" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r1300" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r1341" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r1341" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r1341" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquityComponentDomain", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail", "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r17", "r134", "r141", "r142", "r177", "r178", "r179", "r217", "r218", "r219", "r221", "r229", "r231", "r233", "r256", "r333", "r336", "r389", "r466", "r494", "r551", "r569", "r570", "r583", "r584", "r585", "r588", "r648", "r649", "r723", "r725", "r726", "r727", "r728", "r730", "r731", "r732", "r733", "r734", "r745", "r784", "r786", "r787", "r788", "r789", "r790", "r794", "r796", "r806", "r909", "r941", "r942", "r943", "r965", "r1034" ] }, "us-gaap_EquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "EquitySecuritiesMember", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Equity Securities [Member]", "terseLabel": "Equity Securities [Member]", "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants." } } }, "auth_ref": [ "r37", "r1226", "r1254", "r1255", "r1256", "r1651" ] }, "teva_EquityTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "EquityTable", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Equity [Table]" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r1310" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r1268", "r1278", "r1288", "r1320" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r1265", "r1275", "r1285", "r1317" ] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "EuropeMember", "presentation": [ "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" ], "lang": { "en-us": { "role": { "label": "Europe [Member]", "terseLabel": "Europe [Member]" } } }, "auth_ref": [ "r1650", "r1652", "r1653", "r1654" ] }, "teva_EuropeSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "EuropeSegmentMember", "presentation": [ "http://www.tevapharm.com/role/SegmentsParentheticalDetail", "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Europe Segment [Member]", "terseLabel": "Europe [Member]", "documentation": "Europe segment." } } }, "auth_ref": [] }, "teva_EvanLippmanEvpBusinessDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "EvanLippmanEvpBusinessDevelopmentMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Evan Lippman, EVP, Business Development [Member]", "documentation": "" } } }, "auth_ref": [] }, "teva_EventBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "EventBasisAxis", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Event Basis [Axis]", "documentation": "Event basis ." } } }, "auth_ref": [] }, "teva_EventBasisDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "EventBasisDomain", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Event Basis [Domain]", "documentation": "Event basis ." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r1316" ] }, "teva_ExitAndDisposalAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ExitAndDisposalAxis", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "label": "Exit And Disposal [Axis]", "terseLabel": "Exit And Disposal [Axis]", "documentation": "Exit And Disposal [Axis]" } } }, "auth_ref": [] }, "teva_ExitAndDisposalDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ExitAndDisposalDomain", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "label": "Exit And Disposal [Domain]", "terseLabel": "Exit And Disposal [Domain]", "documentation": "Exit And Disposal [Domain]" } } }, "auth_ref": [] }, "teva_ExpectedImpairmentOfIncomeTaxBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ExpectedImpairmentOfIncomeTaxBenefit", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Expected Impairment OF Income Tax Benefit", "terseLabel": "Expected impairment of income tax benefit", "documentation": "Expected impairment of income tax benefit." } } }, "auth_ref": [] }, "teva_FacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "FacilityAxis", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Facility [Axis]", "documentation": "Facility." } } }, "auth_ref": [] }, "teva_FacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "FacilityDomain", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Facility [Domain]", "documentation": "Facility." } } }, "auth_ref": [] }, "teva_FactoringInstitutionAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "FactoringInstitutionAxis", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Factoring Institution [Axis]", "documentation": "Factoring institution." } } }, "auth_ref": [] }, "teva_FactoringInstitutionDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "FactoringInstitutionDomain", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Factoring Institution [Domain]", "documentation": "Factoring institution." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract", "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r749", "r750", "r763", "r1210" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r749", "r750", "r763", "r1210" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "verboseLabel": "Summary of Financial Instrument Measured on a Basis Other Than Fair Value", "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2." } } }, "auth_ref": [ "r749", "r750" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "terseLabel": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r754", "r755", "r756", "r757", "r758", "r759", "r764", "r1083", "r1213", "r1222" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "terseLabel": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r754", "r755", "r756", "r757", "r758", "r759", "r764", "r1083", "r1213", "r1222" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r450", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r748", "r750", "r751", "r752", "r753", "r762", "r763", "r765", "r773", "r814", "r815", "r816", "r1083", "r1132", "r1133", "r1146", "r1147", "r1148", "r1149", "r1150", "r1210", "r1215", "r1222" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r754", "r755", "r756", "r757", "r758", "r759", "r764" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurement" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair value measurement", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r751", "r758", "r760", "r761", "r762", "r765", "r766", "r767", "r768", "r769", "r882", "r1210", "r1216" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r450", "r508", "r513", "r514", "r750", "r763", "r773", "r814", "r1083", "r1146", "r1147", "r1148", "r1149", "r1150", "r1210", "r1222" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r450", "r508", "r513", "r514", "r516", "r750", "r751", "r763", "r773", "r815", "r1083", "r1132", "r1133", "r1146", "r1147", "r1148", "r1149", "r1150", "r1210", "r1222" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r450", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r750", "r751", "r752", "r753", "r763", "r773", "r816", "r1083", "r1132", "r1133", "r1146", "r1147", "r1148", "r1149", "r1150", "r1210", "r1215", "r1222" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r754", "r755", "r756", "r757", "r758", "r759", "r764" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "verboseLabel": "Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r754", "r759", "r764" ] }, "teva_FairValueMeasurementTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "FairValueMeasurementTable", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurement", "http://www.tevapharm.com/role/FairValueMeasurementTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement [Table]" } } }, "auth_ref": [] }, "teva_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityContingentConsiderationIncreaseDecrease", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Contingent Consideration Increase Decrease", "terseLabel": "Adjustments to provisions for contingent consideration", "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability contingent consideration increase decrease." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "terseLabel": "Settlement of contingent consideration", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r757", "r764" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "negatedPeriodStartLabel": "Fair value at the beginning of the period", "negatedPeriodEndLabel": "Fair value at the end of the period", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r754", "r764" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r450", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r748", "r750", "r751", "r752", "r753", "r762", "r763", "r765", "r773", "r814", "r815", "r816", "r1083", "r1132", "r1133", "r1146", "r1147", "r1148", "r1149", "r1150", "r1210", "r1215", "r1222" ] }, "us-gaap_FairValueNetAssetLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FairValueNetAssetLiability", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Asset (Liability)", "terseLabel": "Total", "documentation": "Fair value of asset after deduction of liability." } } }, "auth_ref": [ "r1571", "r1572" ] }, "teva_FinancialExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "FinancialExpensesMember", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Financial expenses [Member]", "terseLabel": "Financial expenses [Member]" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r461", "r491", "r719", "r735", "r770", "r777", "r780", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r826", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r896", "r910", "r1122", "r1210", "r1213", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1226", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365", "r1366", "r1458", "r1459", "r1460", "r1461", "r1570", "r1573", "r1574", "r1575", "r1582", "r1585", "r1586", "r1587" ] }, "teva_FineForViolatingTheAntitrustLawsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "FineForViolatingTheAntitrustLawsMember", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Fine for Violating the Antitrust Laws [Member]", "documentation": "Fine for violating the antitrust laws." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Amortization of intangible assets useful life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r152", "r349", "r379", "r1086" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r372", "r374", "r375", "r376", "r378", "r379", "r381", "r382", "r846", "r847", "r953", "r1082", "r1086", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross carrying amount net of impairment", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r349", "r379", "r847", "r1086" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r372", "r379", "r381", "r382", "r386", "r846", "r1082", "r1086", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r372", "r374", "r375", "r376", "r378", "r379", "r381", "r382", "r953", "r1082", "r1086", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Identifiable intangible assets, net", "totalLabel": "Net carrying amount", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r846", "r1481" ] }, "teva_FivePointSevenFiveSeniorNotesDue2030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "FivePointSevenFiveSeniorNotesDue2030Member", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Five Point Seven Five Senior Notes Due 2030 [Member]", "verboseLabel": "5.75% senior notes due 2030 [Member]", "documentation": "5.75% senior notes due 2030." } } }, "auth_ref": [] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ForeignExchangeContractMember", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r1097", "r1146", "r1148", "r1193", "r1194", "r1196", "r1197", "r1198", "r1199", "r1200", "r1201", "r1202", "r1203", "r1204", "r1206", "r1210", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1379", "r1380", "r1563" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r1272", "r1282", "r1292", "r1324" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r1272", "r1282", "r1292", "r1324" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r1272", "r1282", "r1292", "r1324" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r1272", "r1282", "r1292", "r1324" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1272", "r1282", "r1292", "r1324" ] }, "teva_FormerShareholdersMilestonePaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "FormerShareholdersMilestonePaymentMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Former Shareholders Milestone Payment [Member]" } } }, "auth_ref": [] }, "teva_ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses", "terseLabel": "Forward starting interest rate swaps and treasury lock agreements losses", "documentation": "Forward starting interest rate swaps and treasury lock agreements losses." } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r1305" ] }, "us-gaap_FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "FreshStartAdjustmentsTypeOfFreshStartAdjustmentAxis", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Fresh-Start Adjustments [Axis]", "terseLabel": "Fresh-Start Adjustments [Axis]", "documentation": "Information by adjustment for effect of reorganization under Chapter 11 of Bankruptcy Code. Includes, but is not limited to, adjustment for reorganization plan effect and adoption of fresh-start reporting." } } }, "auth_ref": [ "r808", "r809", "r1224" ] }, "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GainLossOnDerivativeInstrumentsNetPretax", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Derivative Instruments, Net, Pretax", "terseLabel": "Gain (Loss) on Derivative Instruments, Net, Pretax", "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects." } } }, "auth_ref": [ "r1554" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "verboseLabel": "General and administrative expenses", "terseLabel": "G&A expenses", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r89", "r1018" ] }, "teva_GenericPipelineProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "GenericPipelineProductsMember", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Generic Pipeline Products [Member]" } } }, "auth_ref": [] }, "teva_GenericsMediciansIncludingOtcAndBiosimilarsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "GenericsMediciansIncludingOtcAndBiosimilarsMember", "presentation": [ "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "Generics Medicians Including OTC And Biosimilars [Member]", "terseLabel": "Generic products (including OTC and biosimilars) [Member]", "documentation": "Generics medicians including OTC and biosimilars." } } }, "auth_ref": [] }, "teva_GoodWillRelativeFairValueAllocation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "GoodWillRelativeFairValueAllocation", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" ], "lang": { "en-us": { "role": { "label": "Good will Relative Fair Value Allocation", "verboseLabel": "Goodwill allocation related to the shift of Anda to Other Activities", "documentation": "Good will Relative Fair Value Allocation." } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" ], "lang": { "en-us": { "role": { "label": "Goodwill", "terseLabel": "Goodwill", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r151", "r351", "r883", "r1116", "r1123", "r1155", "r1156", "r1157", "r1189", "r1212", "r1224", "r1464", "r1471", "r1546" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "teva_GoodwillAndIntangibleAssetsDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "GoodwillAndIntangibleAssetsDisclosureTable", "presentation": [ "http://www.tevapharm.com/role/Goodwill", "http://www.tevapharm.com/role/GoodwillTables", "http://www.tevapharm.com/role/IdentifiableIntangibleAssets", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Table]" } } }, "auth_ref": [] }, "us-gaap_GoodwillDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GoodwillDisclosureTextBlock", "presentation": [ "http://www.tevapharm.com/role/Goodwill" ], "lang": { "en-us": { "role": { "label": "Goodwill Disclosure [Text Block]", "terseLabel": "Goodwill", "documentation": "The entire disclosure for goodwill." } } }, "auth_ref": [ "r350", "r352", "r362", "r364", "r365", "r367", "r369", "r370", "r1123" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" ], "lang": { "en-us": { "role": { "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "negatedLabel": "Translation differences and other", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r358", "r644" ] }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Goodwill, Impaired, Accumulated Impairment Loss", "terseLabel": "Accumulated goodwill impairment", "documentation": "Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r353", "r360", "r368", "r644", "r1123" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GoodwillLineItems", "presentation": [ "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail", "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r363", "r1123" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GoodwillRollForward", "lang": { "en-us": { "role": { "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Gross Profit", "totalLabel": "Gross profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r83", "r87", "r124", "r200", "r205", "r206", "r332", "r425", "r426", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r778", "r1110", "r1115", "r1444", "r1452", "r1453", "r1454", "r1455", "r1501" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r1554", "r1556" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r1554", "r1556" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [] }, "teva_ImpairmentAndRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ImpairmentAndRestructuring", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" ], "lang": { "en-us": { "role": { "label": "Impairment And Restructuring", "totalLabel": "Total", "documentation": "Impairment and restructuring." } } }, "auth_ref": [] }, "us-gaap_ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ImpairmentIntangibleAssetStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of intangible asset. Includes, but is not limited to, finite-lived and indefinite-lived intangible assets." } } }, "auth_ref": [ "r385" ] }, "us-gaap_ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" ], "lang": { "en-us": { "role": { "label": "Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]", "verboseLabel": "Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of long-lived asset held for use." } } }, "auth_ref": [ "r390" ] }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Impairment of intangible assets excluding goodwill", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value." } } }, "auth_ref": [ "r12", "r186", "r373", "r384" ] }, "teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ImpairmentOfIntangibleAssetsReasonsForImpairmentAxis", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Impairment Of Intangible Assets Reasons For Impairment [Axis]", "documentation": "Impairment Of Intangible Assets Reasons For Impairment." } } }, "auth_ref": [] }, "teva_ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ImpairmentOfIntangibleAssetsReasonsForImpairmentDomain", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Impairment Of Intangible Assets Reasons For Impairment [Domain]", "documentation": "Impairment Of Intangible Assets Reasons For Impairment." } } }, "auth_ref": [] }, "teva_ImpairmentOfLongLivedAssetsAndAssetsHeldForSaleFiniteAndIndefiniteLivedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ImpairmentOfLongLivedAssetsAndAssetsHeldForSaleFiniteAndIndefiniteLivedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Impairment Of Long Lived Assets And Assets Held For Sale Finite And Indefinite Lived Intangible Assets Other Than Goodwill", "terseLabel": "Impairment of long-lived assets and assets held for sale", "documentation": "Impairment of long lived assets and assets held for sale finite and indefinite lived intangible assets other than goodwill." } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": { "parentTag": "teva_ImpairmentAndRestructuring", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" ], "lang": { "en-us": { "role": { "label": "Impairment, Long-Lived Asset, Held-for-Use", "terseLabel": "Impairment of long-lived tangible assets", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r12", "r38", "r98", "r187", "r1101", "r1211" ] }, "teva_ImpairmentsRestructuringAndOthers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ImpairmentsRestructuringAndOthers", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Impairments Restructuring And Others", "verboseLabel": "Other assets impairments, restructuring and other items", "terseLabel": "Other asset impairments, restructuring and other items", "documentation": "Impairments restructuring and others." } } }, "auth_ref": [] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "In Process Research and Development [Member]", "terseLabel": "In process research and development [Member]", "verboseLabel": "In process research and development [Member]", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [ "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1481", "r1482", "r1483", "r1484" ] }, "teva_IncomeLossFromContinuingOperationsBeforeIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxes", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes", "terseLabel": "Pre-tax income (loss)", "documentation": "Income (Loss) from Continuing Operations before Income Taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes", "presentationGuidance": "Consolidated income (loss) before income taxes", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": [ "r124", "r915", "r1110", "r1241", "r1242", "r1444", "r1452", "r1453", "r1454", "r1455" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Equity Method Investments", "verboseLabel": "Share\u00a0in (profits)\u00a0losses of\u00a0associated\u00a0companies, net", "negatedLabel": "Share\u00a0in (profits)\u00a0losses of\u00a0associated\u00a0companies, net", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r12", "r84", "r120", "r255", "r273", "r289", "r331", "r905" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "terseLabel": "Income Statement Location [Axis]", "documentation": "Information by location in statement of income where disaggregated amount is reported." } } }, "auth_ref": [ "r391", "r398", "r407", "r671", "r678", "r695", "r704", "r755", "r759", "r764", "r779", "r780", "r781", "r936", "r938", "r1019", "r1082", "r1083", "r1155", "r1157", "r1206", "r1208", "r1214", "r1222", "r1541", "r1543", "r1611" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "terseLabel": "Income Statement Location [Domain]", "documentation": "Location in statement of income where disaggregated amount is reported." } } }, "auth_ref": [ "r398", "r407", "r671", "r678", "r695", "r704", "r755", "r759", "r764", "r779", "r780", "r781", "r936", "r938", "r1019", "r1082", "r1083", "r1155", "r1157", "r1206", "r1208", "r1214", "r1222", "r1541", "r1543", "r1611" ] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": [ "r565", "r1540" ] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxAuthorityNameDomain", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]", "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [ "r565", "r1540" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r200", "r207", "r557", "r561", "r562", "r563", "r564", "r566", "r567", "r575", "r577", "r578", "r579", "r895", "r952", "r962", "r1154" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "terseLabel": "Income taxes (benefit)", "verboseLabel": "Tax benefit", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r128", "r129", "r200", "r232", "r233", "r255", "r274", "r289", "r560", "r561", "r576", "r916", "r1102", "r1104", "r1106", "r1154" ] }, "teva_IncomeTaxLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "IncomeTaxLineItems", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Income Tax [Line Items]", "terseLabel": "Income Tax [Line Items]", "documentation": "Income Tax [Line Items]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxReconciliationTaxSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncomeTaxReconciliationTaxSettlements", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Amount, Total", "terseLabel": "Effective Income Tax Rate Reconciliation, Tax Settlement, Amount, Total", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements." } } }, "auth_ref": [ "r1537", "r1538" ] }, "teva_IncomeTaxTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "IncomeTaxTable", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Income Tax [Table]", "terseLabel": "Income Tax [Table]", "documentation": "Income Tax [Table]" } } }, "auth_ref": [] }, "teva_IncreaseDecreaseInCertainCurrentAssetsExcludingInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "IncreaseDecreaseInCertainCurrentAssetsExcludingInventories", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase Decrease In Certain Current Assets Excluding Inventories", "terseLabel": "Trade receivables net of sales reserves and allowances", "documentation": "Increase decrease in certain current assets excluding inventories." } } }, "auth_ref": [] }, "teva_IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase Decrease In Certain Current Liabilities Excluding Debt", "terseLabel": "Trade payables, accrued expenses, employee-related obligations and other liabilities", "documentation": "Increase decrease in certain current liabilities excluding debt." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "terseLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInOperatingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOperatingCapital", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 22.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital", "negatedLabel": "Net change in operating assets and liabilities", "documentation": "Amount of increase (decrease) in asset and (increase) decrease in liability, used in operating activity in reconciling net income to reflect cash provided by (used in) operating activity when indirect cash flow method is applied." } } }, "auth_ref": [ "r11" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Net change in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Current Assets", "terseLabel": "Other assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r1428" ] }, "teva_IncreaseInDevelopmentFundingCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "IncreaseInDevelopmentFundingCommitment", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Increase in development funding commitment", "terseLabel": "Increase in development funding commitment", "documentation": "Increase in development funding commitment." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock", "presentation": [ "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock", "terseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method." } } }, "auth_ref": [ "r244", "r245", "r250", "r553", "r554" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r1272", "r1282", "r1292", "r1316", "r1324", "r1328", "r1336" ] }, "teva_InitialCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "InitialCommitmentMember", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Initial Commitment [Member]", "documentation": "Initial Commitment." } } }, "auth_ref": [] }, "teva_InprocessresearchandDevelopmenttoProductRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "InprocessresearchandDevelopmenttoProductRightsMember", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "In Process Research And Development To Product Rights [Member]", "terseLabel": "In Process Research And Development To Product Rights [Member]", "documentation": "In Process Research And Development To Product Rights [Member]" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r1334" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r1264", "r1340" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r1264", "r1340" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r1264", "r1340" ] }, "teva_InstitutionAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "InstitutionAxis", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Institution [Axis]", "documentation": "Institution." } } }, "auth_ref": [] }, "teva_InstitutionDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "InstitutionDomain", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Institution [Domain]", "documentation": "Institution." } } }, "auth_ref": [] }, "teva_IntangibleAssetImpairments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "IntangibleAssetImpairments", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Intangible Asset Impairments", "terseLabel": "Intangible asset impairments", "documentation": "Intangible Asset Impairments." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Identifiable intangible assets", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r371", "r383", "r387", "r1081", "r1082" ] }, "teva_IntangibleAssetsImpairments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "IntangibleAssetsImpairments", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Intangible Assets Impairments", "terseLabel": "Intangible assets impairments", "documentation": "Intangible Assets Impairments" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InterestRateSwapMember", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Interest Rate Swap [Member]", "terseLabel": "Asset Derivatives - Options and Forward Contracts [Member]", "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } }, "auth_ref": [ "r1205", "r1251", "r1252", "r1561" ] }, "teva_InternationalMarketsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "InternationalMarketsMember", "presentation": [ "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail", "http://www.tevapharm.com/role/SegmentsParentheticalDetail", "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "International Markets [Member]", "terseLabel": "International Markets [Member]", "documentation": "International markets." } } }, "auth_ref": [] }, "teva_InventoriesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "InventoriesLineItems", "presentation": [ "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail" ], "lang": { "en-us": { "role": { "label": "Inventories [Line Items]", "terseLabel": "Inventories [Line Items]", "documentation": "Inventories [Line Items]" } } }, "auth_ref": [] }, "teva_InventoriesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "InventoriesTable", "presentation": [ "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail" ], "lang": { "en-us": { "role": { "label": "Inventories [Table]", "terseLabel": "Inventories [Table]", "documentation": "Inventories [Table]" } } }, "auth_ref": [] }, "us-gaap_InventoryCurrentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryCurrentTable", "presentation": [ "http://www.tevapharm.com/role/Inventories", "http://www.tevapharm.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "label": "Inventory, Current [Table]", "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.tevapharm.com/role/Inventories" ], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r346" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail" ], "lang": { "en-us": { "role": { "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished products", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r96", "r1090" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 10.0 }, "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail" ], "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r162", "r1088", "r1224" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail" ], "lang": { "en-us": { "role": { "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw and packaging materials", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r96", "r1092" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail" ], "lang": { "en-us": { "role": { "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Products in process", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r96", "r1091" ] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Investments, Fair Value Disclosure", "terseLabel": "Investment in securities", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": [ "r1571", "r1572", "r1582", "r1586", "r1587", "r1588", "r1589" ] }, "us-gaap_IsraelTaxAuthorityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "IsraelTaxAuthorityMember", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Israel Tax Authority [Member]", "terseLabel": "Israel Tax Authority [Member]", "documentation": "Designated tax department of the government of Israel." } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeaseContractualTermAxis", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": [ "r800", "r1357" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LeaseContractualTermDomain", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": [ "r800", "r1357" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LegalEntityAxis", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail", "http://www.tevapharm.com/role/CertainTransactions", "http://www.tevapharm.com/role/CertainTransactionsTables", "http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows", "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/DebtObligations", "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtParentheticalDetail", "http://www.tevapharm.com/role/DebtObligationsTables", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail", "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail", "http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail", "http://www.tevapharm.com/role/FairValueMeasurement", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail", "http://www.tevapharm.com/role/FairValueMeasurementTables", "http://www.tevapharm.com/role/Goodwill", "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail", "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail", "http://www.tevapharm.com/role/GoodwillTables", "http://www.tevapharm.com/role/IdentifiableIntangibleAssets", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables", "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.tevapharm.com/role/Inventories", "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail", "http://www.tevapharm.com/role/InventoriesTables", "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables", "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail", "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LegalMattersAndContingenciesTextBlock", "presentation": [ "http://www.tevapharm.com/role/LegalSettlementsAndLossContingencies" ], "lang": { "en-us": { "role": { "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Legal Settlements and Loss Contingencies", "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies." } } }, "auth_ref": [ "r104" ] }, "teva_LegalSettlementsAndLossContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "LegalSettlementsAndLossContingencies", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Legal Settlements And Loss Contingencies", "terseLabel": "Legal settlements and loss contingencies", "documentation": "The net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) litigation reserves extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims and the aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items)." } } }, "auth_ref": [] }, "teva_LegalSettlementsAndLossContingenciesUnallocatedToSegments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "LegalSettlementsAndLossContingenciesUnallocatedToSegments", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Legal Settlements And Loss Contingencies Unallocated To Segments", "terseLabel": "Legal settlements and loss contingencies", "documentation": "The net proceeds or assets obtained in excess of (less than) the net carrying amount of assets recorded, or assets distributed and liabilities assumed less than (in excess of) litigation reserves extinguished, in settlement of a litigation matter. Represents (for other than an insurance entity in its normal claims settlement process), the amount of income (expense) recognized in the period to settle pending or threatened litigation and insurance claims and the aggregate amount provided for estimated restructuring charges, remediation costs, and asset impairment loss during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items)." } } }, "auth_ref": [] }, "teva_LegalSettlementsLossContingenciesImpairmentsOtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "LegalSettlementsLossContingenciesImpairmentsOtherExpenses", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": { "parentTag": "teva_ImpairmentAndRestructuring", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" ], "lang": { "en-us": { "role": { "label": "Legal Settlements Loss Contingencies Impairments Other Expenses", "terseLabel": "Other", "documentation": "Legal settlements loss contingencies impairments other expenses." } } }, "auth_ref": [] }, "teva_LeverageRatio": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "LeverageRatio", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Leverage Ratio", "terseLabel": "Leverage Ratio", "documentation": "Leverage ratio." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r21", "r60", "r61", "r62", "r65", "r66", "r67", "r68", "r200", "r205", "r206", "r332", "r425", "r426", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r653", "r657", "r658", "r778", "r995", "r1109", "r1136", "r1259", "r1501", "r1598", "r1599" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r75", "r119", "r903", "r1224", "r1241", "r1242", "r1430", "r1435", "r1462", "r1590" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r62", "r149", "r200", "r205", "r206", "r332", "r425", "r426", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r653", "r657", "r658", "r778", "r1224", "r1501", "r1598", "r1599" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "teva_LiabilitiesHeldForSaleCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "LiabilitiesHeldForSaleCurrent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 22.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities Held For Sale Current", "terseLabel": "Liabilities held for sale", "documentation": "Liabilities held for sale current." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 23.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r21", "r65", "r66", "r67", "r68", "r200", "r205", "r206", "r332", "r425", "r426", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r653", "r657", "r658", "r778", "r1501", "r1598", "r1599" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities", "negatedLabel": "Total liabilities of the disposal group classified as held for sale in the consolidated balance sheets", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1", "r55", "r57", "r99", "r146", "r147" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "negatedLabel": "Other current liabilities", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r55", "r57", "r97", "r99", "r146", "r147" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsBusinessAcquisitionsSummaryOfMajorClassesOfAssetsAndLiabilitiesIncludedAsHeldForSaleDetail" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent", "negatedLabel": "Other non-current liabilities", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r6", "r55", "r57", "r99", "r146", "r147" ] }, "teva_LicenseAgreementPotentialAggregateMilestonePaymentsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "LicenseAgreementPotentialAggregateMilestonePaymentsAmount", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "License Agreement Potential Aggregate Milestone Payments Amount", "verboseLabel": "License agreement potential aggregate milestone payments amount", "documentation": "License agreement potential aggregate milestone payments amount." } } }, "auth_ref": [] }, "us-gaap_LicenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LicenseMember", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" ], "lang": { "en-us": { "role": { "label": "License [Member]", "terseLabel": "Licensing Arrangements [Member]", "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark." } } }, "auth_ref": [ "r1506", "r1507" ] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r59", "r64", "r1430", "r1433", "r1498", "r1499" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r59", "r64", "r1430", "r1433", "r1498", "r1499" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r59", "r64" ] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "LitigationCaseAxis", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "LitigationCaseTypeDomain", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "teva_LitigationFineAmountOfCopaxone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "LitigationFineAmountOfCopaxone", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Fine Amount Of Copaxone", "terseLabel": "Litigation fine amount of copaxone", "documentation": "Litigation fine amount of copaxone." } } }, "auth_ref": [] }, "teva_LitigationSettlementAmountAwardedDistributionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "LitigationSettlementAmountAwardedDistributionPeriod", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Settlement Amount Awarded Distribution Period", "terseLabel": "Litigation settlement amount awarded distribution period", "documentation": "Litigation settlement amount awarded distribution period." } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Litigation settlement amount", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "teva_LitigationSettlementAmountDistributableInCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "LitigationSettlementAmountDistributableInCash", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Settlement Amount Distributable in Cash", "terseLabel": "Litigation Settlement Amount Distributable in cash", "documentation": "Litigation settlement amount distributable in cash." } } }, "auth_ref": [] }, "teva_LitigationSettlementAmountDistributableinKind": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "LitigationSettlementAmountDistributableinKind", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Settlement Amount DistributableIn Kind", "terseLabel": "Litigation Settlement Amount Distributable In Kind", "documentation": "Litigation settlement amount distributableIn kind." } } }, "auth_ref": [] }, "teva_LitigationSettlementAmountPayableInCashPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "LitigationSettlementAmountPayableInCashPercentage", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation settlement amount payable in cash percentage", "terseLabel": "Percentgae of amount in cash settlement", "documentation": "Litigation settlement amount payable in cash percentage" } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LitigationSettlementExpense", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Settlement, Expense", "terseLabel": "Legal settlements and loss contingencies, expenses", "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees." } } }, "auth_ref": [ "r1359" ] }, "us-gaap_LitigationStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LitigationStatusAxis", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Status [Axis]", "documentation": "Information by status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r1486", "r1487", "r1488", "r1493" ] }, "us-gaap_LitigationStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LitigationStatusDomain", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Litigation Status [Domain]", "documentation": "Status of pending, threatened, or settled litigation." } } }, "auth_ref": [ "r1486", "r1487", "r1488", "r1493" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "teva_LongTermDebtCurrencyPortionUSD": { "xbrltype": "percentItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "LongTermDebtCurrencyPortionUSD", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long Term Debt Currency Portion U S D", "terseLabel": "Long term debt currency portion USD", "documentation": "Long term debt currency portion U S D." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "Long-term Debt, Current Maturities", "terseLabel": "Current maturities of long-term liabilities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r155" ] }, "teva_LongTermDebtExcludingConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "LongTermDebtExcludingConvertibleDebtTableTextBlock", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsTables" ], "lang": { "en-us": { "role": { "label": "Long Term Debt Excluding Convertible Debt Table [Text Block]", "terseLabel": "Schedule of Long-term debt", "documentation": "A schedule of data and information pertaining to long-debt instruments or arrangements, excluding convertible debt, that includes identification, terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_LongTermNotesAndLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermNotesAndLoans", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 26.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail" ], "lang": { "en-us": { "role": { "label": "Notes and Loans, Noncurrent", "terseLabel": "Senior notes and loans", "verboseLabel": "Total senior notes and loans", "documentation": "Carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r21" ] }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Category of Item Purchased [Axis]", "terseLabel": "Category of Item Purchased [Axis]", "documentation": "Information by category of items purchased under a long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long-term Purchase Commitment, Category of Item Purchased [Domain]", "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased [Domain]", "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r21", "r1486", "r1487", "r1488" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r21", "r42", "r1486", "r1487", "r1488" ] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r261", "r415", "r416", "r417", "r421", "r555", "r951", "r1130", "r1494", "r1495" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r261", "r415", "r416", "r417", "r421", "r555", "r1130", "r1494", "r1495" ] }, "teva_LossContingenciesOnEnvironmentalLawsPenalty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "LossContingenciesOnEnvironmentalLawsPenalty", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies On Environmental Laws Penalty", "terseLabel": "Loss Contingencies On Environmental Laws Penalty", "documentation": "Loss contingencies on environmental laws penalty." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LossContingenciesTable", "presentation": [ "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r261", "r415", "r416", "r417", "r421", "r555", "r1130", "r1494", "r1495" ] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual", "terseLabel": "Accrued amount for legal settlements and loss contingencies", "verboseLabel": "Generic modafinil, and imposed fines amount", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r415", "r1351" ] }, "us-gaap_LossContingencyAccrualCarryingValueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LossContingencyAccrualCarryingValueCurrent", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency, Accrual, Current", "terseLabel": "Loss contingency accrual current", "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r415" ] }, "teva_LossContingencyAccrualDueInFifthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "LossContingencyAccrualDueInFifthYear", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual Due In Fifth Year", "terseLabel": "Loss contingency accrual due in fifth year", "documentation": "Loss contingency accrual due in fifth year." } } }, "auth_ref": [] }, "teva_LossContingencyAccrualDueInFourthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "LossContingencyAccrualDueInFourthYear", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual Due In Fourth Year", "terseLabel": "Loss contingency accrual due in fourth year", "documentation": "Loss contingency accrual due in fourth year." } } }, "auth_ref": [] }, "teva_LossContingencyAccrualDueInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "LossContingencyAccrualDueInYearThree", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual Due In Year Three", "terseLabel": "Loss contingency accrual due in third year", "documentation": "Loss contingency accrual due in year three." } } }, "auth_ref": [] }, "teva_LossContingencyAccrualNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "LossContingencyAccrualNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual Next Twelve Months", "terseLabel": "Loss contingency accrual next twelve months", "documentation": "Loss contingency accrual next twelve months." } } }, "auth_ref": [] }, "us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueInFifthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LossContingencyAccrualProductLiabilityUndiscountedDueInFifthYear", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual, Product Liability, Undiscounted, to be Paid, Year Five", "terseLabel": "Loss contingency accrual, product liability, undiscounted, to be paid, year five", "documentation": "Undiscounted amount of accrual for damage arising from third-party use of product or process to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r418" ] }, "us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueInFourthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LossContingencyAccrualProductLiabilityUndiscountedDueInFourthYear", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual, Product Liability, Undiscounted, to be Paid, Year Four", "terseLabel": "Loss contingency accrual, product liability, undiscounted, to be paid, year four", "documentation": "Undiscounted amount of accrual for damage arising from third-party use of product or process to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r418" ] }, "us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueInSecondYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LossContingencyAccrualProductLiabilityUndiscountedDueInSecondYear", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual, Product Liability, Undiscounted, to be Paid, Year Two", "terseLabel": "Loss contingency accrual, product liability, undiscounted, to be paid, year two", "documentation": "Undiscounted amount of accrual for damage arising from third-party use of product or process to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r418" ] }, "us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueInThirdYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LossContingencyAccrualProductLiabilityUndiscountedDueInThirdYear", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual, Product Liability, Undiscounted, to be Paid, Year Three", "terseLabel": "Loss contingency accrual, product liability, undiscounted, to be paid, year three", "documentation": "Undiscounted amount of accrual for damage arising from third-party use of product or process to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r418" ] }, "us-gaap_LossContingencyAccrualProductLiabilityUndiscountedDueWithinOneYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LossContingencyAccrualProductLiabilityUndiscountedDueWithinOneYear", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual, Product Liability, Undiscounted, to be Paid, Year One", "terseLabel": "Loss contingency accrual, product liability, undiscounted, to be paid, year one", "documentation": "Undiscounted amount of accrual for damage arising from third-party use of product or process to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r418" ] }, "us-gaap_LossContingencyAccrualProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LossContingencyAccrualProvision", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual, Provision", "terseLabel": "Loss Contingency Accrual, Provision", "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges." } } }, "auth_ref": [ "r1493" ] }, "teva_LossContingencyAccrualRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "LossContingencyAccrualRemainderOfFiscalYear", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency Accrual Remainder Of Fiscal Year", "terseLabel": "Loss contingency accrual remainder of fiscal year", "documentation": "Loss contingency accrual remainder of fiscal year." } } }, "auth_ref": [] }, "teva_LossContingencyAggregatePaymentsPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "LossContingencyAggregatePaymentsPaid", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency Aggregate Payments Paid", "terseLabel": "Loss contingency aggregate payments paid", "documentation": "Loss contingency aggregate payments paid." } } }, "auth_ref": [] }, "teva_LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "LossContingencyClaimsDismissedValuePaidToEachStateProportionalToItsShareOfNationalPopulation", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population", "terseLabel": "Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population", "documentation": "Loss contingency claims dismissed value paid to each state proportional to its share of national population" } } }, "auth_ref": [] }, "us-gaap_LossContingencyDamagesAwardedValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LossContingencyDamagesAwardedValue", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency, Damages Awarded, Value", "terseLabel": "Loss Contingency, Damages Awarded, Value", "documentation": "Amount of damages awarded to the plaintiff in the legal matter." } } }, "auth_ref": [ "r1493", "r1494", "r1495" ] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "LossContingencyNatureDomain", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r261", "r415", "r416", "r417", "r421", "r555", "r951", "r1130", "r1494", "r1495" ] }, "teva_MabxienceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "MabxienceMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "mAbxience [Member]", "documentation": "mAbxience." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MaximumMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical", "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "auth_ref": [ "r261", "r416", "r417", "r419", "r420", "r518", "r544", "r545", "r546", "r555", "r753", "r844", "r935", "r937", "r951", "r987", "r988", "r1039", "r1041", "r1043", "r1044", "r1054", "r1063", "r1064", "r1066", "r1067", "r1079", "r1080", "r1121", "r1137", "r1153", "r1155", "r1158", "r1159", "r1215", "r1216", "r1220", "r1221", "r1236", "r1503", "r1600", "r1601", "r1602", "r1603", "r1604", "r1605" ] }, "teva_MaximumTaxPaymentLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "MaximumTaxPaymentLimit", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Maximum Tax Payment Limit", "terseLabel": "Maximum tax payment limit", "documentation": "Maximum tax payment limit." } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r1308" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1308" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Measurement input, discount rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r1155", "r1158", "r1159", "r1573", "r1574", "r1575" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r542", "r543", "r544", "r545", "r546", "r547", "r751", "r752", "r753", "r1155", "r1158", "r1159", "r1215" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r751", "r752", "r753", "r1155", "r1158", "r1159", "r1215" ] }, "teva_MedicaidAndOtherGovernmentalAllowancesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "MedicaidAndOtherGovernmentalAllowancesMember", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "Medicaid And Other Governmental Allowances [Member]", "terseLabel": "Medicaid and other governmental allowances [Member]", "documentation": "Medicaid and other governmental allowances." } } }, "auth_ref": [] }, "teva_MedincellMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "MedincellMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "MedinCell [Member]", "documentation": "MedinCell [ Member]." } } }, "auth_ref": [] }, "teva_MilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "MilestonePayment", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Milestone Payment", "terseLabel": "Milestone payment", "documentation": "Milestone payment." } } }, "auth_ref": [] }, "teva_MilestonePaymentReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "MilestonePaymentReceivable", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Milestone Payment Receivable", "terseLabel": "Milestone payment receivable", "documentation": "Milestone payment receivable." } } }, "auth_ref": [] }, "teva_MilestonePaymentToBePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "MilestonePaymentToBePaid", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Milestone Payment To Be Paid", "documentation": "Milestone payment to be paid." } } }, "auth_ref": [] }, "teva_Milestonepaymentpercentagecap": { "xbrltype": "percentItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "Milestonepaymentpercentagecap", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "MilestonePaymentPercentageCap", "terseLabel": "Milestone payment percentage cap", "documentation": "Milestone payment percentage cap." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "MinimumMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical", "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "auth_ref": [ "r261", "r416", "r417", "r419", "r420", "r518", "r544", "r545", "r546", "r555", "r753", "r844", "r935", "r937", "r951", "r987", "r988", "r1039", "r1041", "r1043", "r1044", "r1054", "r1063", "r1064", "r1066", "r1067", "r1079", "r1080", "r1121", "r1137", "r1153", "r1155", "r1158", "r1159", "r1215", "r1216", "r1220", "r1236", "r1503", "r1600", "r1601", "r1602", "r1603", "r1604", "r1605" ] }, "teva_MinimumTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "MinimumTaxRate", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Minimum Tax Rate", "terseLabel": "Minimum tax rate", "documentation": "Minimum tax rate." } } }, "auth_ref": [] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 29.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Non-controlling interests", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r74", "r118", "r200", "r205", "r206", "r332", "r425", "r428", "r429", "r430", "r434", "r435", "r902", "r998", "r1590" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r1327" ] }, "teva_ModafinilSettlementAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ModafinilSettlementAgreementMember", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Modafinil Settlement Agreement [Member]", "documentation": "Modafinil settlement agreement." } } }, "auth_ref": [] }, "teva_ModagMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ModagMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Modag [Member]", "terseLabel": "MODAG [Member]", "documentation": "Modag ." } } }, "auth_ref": [] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "terseLabel": "Money Markets [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r1508", "r1509" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r1335" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r1309" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities", "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit." } } }, "auth_ref": [ "r198" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets." } } }, "auth_ref": [ "r198" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities", "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity." } } }, "auth_ref": [ "r92", "r93", "r94" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities:" } } }, "auth_ref": [] }, "teva_NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information", "totalLabel": "Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information", "documentation": "The net change during the reporting period in the amounts of the current assets and current liabilities that are reported in the supplemental disclosure of information section of the Consolidated Statements of Cash Flows." } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) attributable to Teva", "presentationGuidance": "Net income (loss)", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r88", "r94", "r121", "r142", "r147", "r172", "r175", "r179", "r200", "r205", "r206", "r208", "r220", "r225", "r226", "r227", "r228", "r229", "r232", "r233", "r246", "r332", "r425", "r426", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r467", "r470", "r473", "r477", "r551", "r587", "r649", "r747", "r778", "r908", "r1015", "r1032", "r1033", "r1102", "r1104", "r1106", "r1257", "r1501" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Net income (loss) attributable to redeemable and non-redeemable non-controlling interests", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r52", "r114", "r172", "r175", "r229", "r232", "r233", "r907", "r1383" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "verboseLabel": "Net income (loss) attributable to Teva's ordinary shareholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r185", "r237", "r240", "r241", "r242", "r243", "r247", "r250" ] }, "teva_NetIncomeLossIncludingNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "NetIncomeLossIncludingNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Net Income Loss Including Noncontrolling Interest", "verboseLabel": "Net income (loss)", "documentation": "Net income loss including noncontrolling interest." } } }, "auth_ref": [] }, "teva_NetRevenuesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "NetRevenuesMember", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Net Revenues [Member]", "terseLabel": "Net Revenues [Member]" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r1308" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r1272", "r1282", "r1292", "r1316", "r1324" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r1299" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r1298" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r1316" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r1335" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r1335" ] }, "us-gaap_NoncashOrPartNoncashAcquisitionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NoncashOrPartNoncashAcquisitionsLineItems", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Noncash or Part Noncash Acquisitions [Line Items]", "terseLabel": "Noncash or Part Noncash Acquisitions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_NoncashOrPartNoncashAcquisitionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NoncashOrPartNoncashAcquisitionsTable", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Noncash or Part Noncash Acquisitions [Table]", "terseLabel": "Noncash or Part Noncash Acquisitions [Table]", "documentation": "Disclosure of information about noncash or part noncash acquisition." } } }, "auth_ref": [ "r29", "r30", "r31" ] }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "terseLabel": "Purchase of shares from non-controlling interests", "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders." } } }, "auth_ref": [ "r15", "r45", "r113" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-controlling Interests [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r48", "r494", "r1438", "r1439", "r1440", "r1441", "r1649" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NondesignatedMember", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "negatedTerseLabel": "Financial expenses, net", "negatedLabel": "Financial expenses, net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r90" ] }, "us-gaap_NotDesignatedAsHedgingInstrumentEconomicHedgeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NotDesignatedAsHedgingInstrumentEconomicHedgeMember", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Not Designated as Hedging Instrument, Economic Hedge [Member]", "terseLabel": "Not Designated as Hedging Instrument, Economic Hedge [Member]", "documentation": "Derivative instrument, not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP), used as economic hedge for exposure to risk." } } }, "auth_ref": [ "r1554", "r1556" ] }, "us-gaap_NotDesignatedAsHedgingInstrumentTradingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NotDesignatedAsHedgingInstrumentTradingMember", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesNotDesignatedInAsHedgingInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Not Designated as Hedging Instrument, Trading [Member]", "terseLabel": "Not Designated as Hedging Instrument, Trading [Member]", "documentation": "Derivative instrument, not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP), used for trading purposes for exposure to risk." } } }, "auth_ref": [ "r1554", "r1556" ] }, "teva_NoveTideAcquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "NoveTideAcquisitionMember", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail" ], "lang": { "en-us": { "role": { "label": "Nove Tide Acquisition [Member]", "documentation": "Nove tide acquisition." } } }, "auth_ref": [] }, "teva_NovemberTwoThousandAndTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "NovemberTwoThousandAndTwentyThreeMember", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "November Two Thousand And Twenty Three [Member]", "terseLabel": "November 2023 [Member]" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r1111", "r1120", "r1451" ] }, "teva_NumberOfYearsSpreadToPayTaxPayable": { "xbrltype": "durationItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "NumberOfYearsSpreadToPayTaxPayable", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Number Of Years Spread To Pay Tax Payable", "terseLabel": "Number of years spread to pay tax payable", "documentation": "Number of years spread to pay tax payable." } } }, "auth_ref": [] }, "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" ], "lang": { "en-us": { "role": { "label": "OCI, before Reclassifications, before Tax, Attributable to Parent", "terseLabel": "Other comprehensive income (loss) before reclassifications", "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": [ "r24" ] }, "teva_OntarioTeachersSecuritiesLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "OntarioTeachersSecuritiesLitigationMember", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Ontario Teachers Securities Litigation [Member]", "documentation": "Ontario teachers securities litigation." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Operating income (loss)", "terseLabel": "Segment profit", "verboseLabel": "Consolidated operating income (loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r124", "r1102", "r1106", "r1110", "r1444", "r1452", "r1453", "r1454", "r1455" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 27.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "definitionGuidance": "Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r798" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "definitionGuidance": "Operating lease right-of-use assets, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r797" ] }, "teva_OpioidLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "OpioidLitigationMember", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Opioid Litigation [Member]" } } }, "auth_ref": [] }, "teva_OptionsAndForwardContractsDerivativeLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "OptionsAndForwardContractsDerivativeLiabilitiesMember", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Options And Forward Contracts Derivative Liabilities [Member]", "terseLabel": "Liabilities Derivatives Options and Forward Contracts [Member]", "documentation": "Options and forward contracts derivative liabilities." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "teva_OtherActivitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "OtherActivitiesMember", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" ], "lang": { "en-us": { "role": { "label": "Other Activities [Member]", "documentation": "Other Activities [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets, Current", "terseLabel": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r164", "r1224" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other\u00a0non-current\u00a0assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r153" ] }, "us-gaap_OtherCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherCommitment", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Other Commitment", "terseLabel": "Other commitment", "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions." } } }, "auth_ref": [ "r1431", "r1437", "r1606" ] }, "us-gaap_OtherCommitmentDueInFifthYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherCommitmentDueInFifthYear", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Other Commitment, to be Paid, Year Five", "terseLabel": "Other commitment, to be paid, year five", "documentation": "Amount of commitment classified as other to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1431", "r1437", "r1606" ] }, "teva_OtherCommitmentToPayForEachYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "OtherCommitmentToPayForEachYear", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Other Commitment to Pay for Each Year", "terseLabel": "Other commitment to pay for each year", "documentation": "Other commitment to pay for each year." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherCommitmentsAxis", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Axis]", "documentation": "Information by type of other commitment." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherCommitmentsDomain", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Domain]", "documentation": "Other future obligation." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherComprehensiveIncomeLocationAxis", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income Location [Axis]", "documentation": "Information by location in other comprehensive income." } } }, "auth_ref": [ "r756", "r759", "r764", "r1083", "r1222" ] }, "us-gaap_OtherComprehensiveIncomeLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherComprehensiveIncomeLocationDomain", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income Location [Domain]", "documentation": "Location in other comprehensive income." } } }, "auth_ref": [ "r756", "r759", "r764", "r1083", "r1222" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent", "totalLabel": "Net other comprehensive income (loss) before tax", "documentation": "Amount before tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r10", "r16", "r112" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax, Parent", "terseLabel": "Other comprehensive income (loss)", "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r169" ] }, "us-gaap_OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), after Tax", "verboseLabel": "Unrealized loss on defined benefit plans", "documentation": "Amount, after tax, of increase (decrease) to other comprehensive income from settlement and curtailment gain (loss) of defined benefit plan." } } }, "auth_ref": [ "r8", "r82", "r111" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Currency translation adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r3", "r909" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax", "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax", "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation." } } }, "auth_ref": [ "r8", "r9", "r82", "r171", "r783" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive income (loss)", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r17", "r20", "r173", "r176", "r180", "r229", "r784", "r785", "r790", "r884", "r909", "r1381", "r1382" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss), net of tax:" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest", "terseLabel": "Foreign currency translation attributable to non-controlling interests", "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests." } } }, "auth_ref": [ "r10", "r16", "r112", "r173", "r176", "r229" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "verboseLabel": "Other comprehensive income (loss)", "totalLabel": "Net other comprehensive income (loss) after tax", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r10", "r16", "r112", "r173", "r176", "r229" ] }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "negatedLabel": "Corresponding income tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r10", "r16", "r112" ] }, "us-gaap_OtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherComprehensiveIncomeMember", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss) [Member]", "terseLabel": "Other Comprehensive Income [Member]", "documentation": "Primary financial statement caption in which reported facts about other comprehensive income have been included." } } }, "auth_ref": [ "r1083", "r1222" ] }, "teva_OtherCountriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "OtherCountriesMember", "presentation": [ "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" ], "lang": { "en-us": { "role": { "label": "Other Countries [Member]", "terseLabel": "Other [Member]", "documentation": "Other countries." } } }, "auth_ref": [] }, "us-gaap_OtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherCurrentAssetsMember", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing other current assets." } } }, "auth_ref": [] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherCurrentLiabilitiesMember", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Other Current Liabilities [Member]", "terseLabel": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] }, "teva_OtherExitAndDisposalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "OtherExitAndDisposalMember", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "label": "Other Exit And Disposal [Member]", "terseLabel": "Other Exit and Disposal [Member]", "documentation": "Other exit and disposal." } } }, "auth_ref": [] }, "teva_OtherExpensesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "OtherExpensesTextBlock", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItems" ], "lang": { "en-us": { "role": { "label": "Other Expenses [Text Block]", "terseLabel": "Other assets impairments, restructuring and other items", "documentation": "Other Expenses [Text Block]" } } }, "auth_ref": [] }, "us-gaap_OtherInventoryInTransit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherInventoryInTransit", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.tevapharm.com/role/InventoriesSummaryOfInventoriesDetail" ], "lang": { "en-us": { "role": { "label": "Other Inventory, in Transit, Gross", "terseLabel": "Materials in transit and payments on account", "documentation": "Gross amount of merchandise or supplies to which the entity holds the title but does not hold physical possession because the goods are currently being transported." } } }, "auth_ref": [ "r1368" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 21.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r61", "r1224" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 25.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other taxes and long-term liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r66" ] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfClassificationAndFairValuesOfDerivativeInstrumentsDetail" ], "lang": { "en-us": { "role": { "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 27.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other items", "documentation": "Amount of cash inflow (outflow) from operating activity, classified as other, in reconciling net income to reflect cash provided by (used in) operating activity when indirect cash flow method is applied." } } }, "auth_ref": [] }, "teva_OtherOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "OtherOperatingIncomeExpense", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Other Operating Income (Expense)", "terseLabel": "Other loss (income)", "documentation": "Other Operating Income (Expense)" } } }, "auth_ref": [] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other Operating Income (Expense), Net", "negatedLabel": "Other loss (income)", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r1308" ] }, "teva_OtherProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "OtherProductsMember", "presentation": [ "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "Other Products [Member]", "terseLabel": "Other [Member]", "documentation": "Other Products [Member]" } } }, "auth_ref": [] }, "teva_OtherRestrictedCashMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "OtherRestrictedCashMember", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Other Restricted Cash [Member]", "terseLabel": "Other [Member]", "documentation": "Other restricted cash." } } }, "auth_ref": [] }, "us-gaap_OtherRestructuringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "OtherRestructuringMember", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "Other Restructuring [Member]", "terseLabel": "Other [Member]", "documentation": "Restructuring and related activities classified as other." } } }, "auth_ref": [ "r1100", "r1126", "r1127", "r1128", "r1129" ] }, "teva_OtherSalesReservesAndAllowancesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "OtherSalesReservesAndAllowancesMember", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "Other Sales Reserves And Allowances [Member]", "terseLabel": "Other [Member]", "documentation": "Other sales reserves and allowances." } } }, "auth_ref": [] }, "teva_OtherThirdPartiesMilestonePaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "OtherThirdPartiesMilestonePaymentMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Other Third Parties Milestone Payment [Member]" } } }, "auth_ref": [] }, "teva_OtherUnallocatedAmounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "OtherUnallocatedAmounts", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Other Unallocated Amounts", "documentation": "Other unallocated amounts." } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1270", "r1280", "r1290", "r1322" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r1273", "r1283", "r1293", "r1325" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1273", "r1283", "r1293", "r1325" ] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ParentMember", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Parent [Member]", "terseLabel": "Total Teva shareholders' equity [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r1297" ] }, "teva_PaymentToAcquireMarketableSecuritiesAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "PaymentToAcquireMarketableSecuritiesAndOtherAssets", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payment To Acquire Marketable Securities And Other Assets", "negatedLabel": "Purchases of investments and other assets", "documentation": "The cash outflow from purchase of available for sales securities and other assets." } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other investing activities", "documentation": "Amount of cash (inflow) outflow from investing activity, classified as other." } } }, "auth_ref": [ "r1353", "r1426" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash consideration", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r27", "r630", "r1155", "r1157", "r1187" ] }, "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsToAcquireEquitySecuritiesFvNi", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Equity Securities, FV-NI", "negatedLabel": "Purchase of Emalex Biosciences outstanding shares, see note 2", "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity." } } }, "auth_ref": [ "r126", "r196" ] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Productive Assets", "negatedLabel": "Purchases of property, plant and equipment and intangible assets", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r127", "r1548", "r1549", "r1550" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r1307" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r1307" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r1299" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r1316" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r1309" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r1298" ] }, "teva_PercentageOfDiscountRateAppliedToTheCashFlows": { "xbrltype": "percentItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "PercentageOfDiscountRateAppliedToTheCashFlows", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Percentage Of Discount Rate Applied To The Cash Flows", "documentation": "Percentage of discount rate applied to the cash flows." } } }, "auth_ref": [] }, "teva_PercentageOfIncreaseDecreaseInContingentConsiderationLiabilities": { "xbrltype": "percentItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "PercentageOfIncreaseDecreaseInContingentConsiderationLiabilities", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Percentage Of Increase Decrease In Contingent Consideration Liabilities", "terseLabel": "Percentage of increase decrease in contingent consideration liabilities", "documentation": "Percentage of increase decrease in contingent consideration liabilities." } } }, "auth_ref": [] }, "teva_PercentageOfShareOfTheNationalPopulation": { "xbrltype": "percentItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "PercentageOfShareOfTheNationalPopulation", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Percentage Of Share Of The National Population", "terseLabel": "Percentage Of Share Of The National Population", "documentation": "Percentage of share of the national population." } } }, "auth_ref": [] }, "teva_PeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "PeriodAxis", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Period [Axis]", "documentation": "Period axsis." } } }, "auth_ref": [] }, "teva_PeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "PeriodDomain", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Period [Domain]", "documentation": "Period domain." } } }, "auth_ref": [] }, "teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "PeriodFromWhichInterestRateIncreaseCouldBeApplicableAxis", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Period From Which Interest Rate Increase Could Be Applicable [Axis]", "documentation": "Period From Which Interest Rate Increase Could Be Applicable." } } }, "auth_ref": [] }, "teva_PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "PeriodFromWhichInterestRateIncreaseCouldBeApplicableDomain", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Period From Which Interest Rate Increase Could Be Applicable [Domain]", "documentation": "Period From Which Interest Rate Increase Could Be Applicable." } } }, "auth_ref": [] }, "teva_Phase2bfundingoptionamount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "Phase2bfundingoptionamount", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Phase2bFundingOptionAmount", "terseLabel": "Phase 2b funding option amount", "documentation": "Phase 2b funding option amount." } } }, "auth_ref": [] }, "teva_Phase3fundingoptionamount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "Phase3fundingoptionamount", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Phase3FundingOptionAmount", "terseLabel": "Phase 3 funding option amount", "documentation": "Phase 3 funding option amount." } } }, "auth_ref": [] }, "us-gaap_PledgingPurposeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PledgingPurposeAxis", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Pledging Purpose [Axis]", "documentation": "Information by pledging purpose of pledged asset owned." } } }, "auth_ref": [ "r200", "r203", "r825", "r1190", "r1225", "r1355" ] }, "us-gaap_PledgingPurposeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PledgingPurposeDomain", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Pledging Purpose [Domain]", "documentation": "Pledging purpose of pledged asset owned." } } }, "auth_ref": [ "r200", "r203", "r825", "r1190", "r1225", "r1355" ] }, "teva_PncBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "PncBankMember", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "PNC Bank [Member]", "documentation": "PNC bank." } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r1300" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r1344" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r1299" ] }, "teva_PolpharmaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "PolpharmaMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Polpharma [Member]" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r163", "r347", "r348", "r1089" ] }, "teva_ProceedFromMinorityNonControllingShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ProceedFromMinorityNonControllingShareholders", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceed From Minority Non Controlling Shareholders", "terseLabel": "Purchase of shares from redeemable and non-redeemable non-controlling interests", "documentation": "Proceed from Minority Non-Controlling Shareholders." } } }, "auth_ref": [] }, "teva_ProceedsFromBeneficialInterestInExchangeForSecuritizedAccountsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ProceedsFromBeneficialInterestInExchangeForSecuritizedAccountsReceivables", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds From Beneficial Interest In Exchange For Securitized Accounts Receivables", "verboseLabel": "Beneficial interest collected in exchange for securitized trade receivables", "documentation": "Proceeds from beneficial interest in exchange for securitized accounts receivables." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Divestiture of Businesses", "verboseLabel": "Proceeds from sale of business and long-lived assets, net", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": [ "r26" ] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other financing activities", "documentation": "Amount of cash inflow (outflow) from financing activity, classified as other." } } }, "auth_ref": [ "r1354", "r1427" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "verboseLabel": "Proceeds from exercise of options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r7", "r18" ] }, "us-gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProductAndServiceOtherMember", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" ], "lang": { "en-us": { "role": { "label": "Product and Service, Other [Member]", "terseLabel": "Other [Member]", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other." } } }, "auth_ref": [ "r1506", "r1507" ] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProductInformationLineItems", "presentation": [ "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "terseLabel": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProductMember", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" ], "lang": { "en-us": { "role": { "label": "Product [Member]", "terseLabel": "Sale of Goods [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r1101", "r1106", "r1138", "r1139" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail", "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "auth_ref": [ "r292", "r845", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r1084", "r1101", "r1104", "r1106", "r1138", "r1139", "r1235", "r1236", "r1237", "r1240", "r1243", "r1356", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1422", "r1423", "r1424", "r1425", "r1496", "r1497", "r1609", "r1612", "r1613", "r1614", "r1615", "r1616", "r1617", "r1618", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1643", "r1644" ] }, "teva_ProductRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ProductRightsMember", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Product Rights [Member]", "terseLabel": "Identifiable product rights [Member]", "verboseLabel": "Product rights [Member]", "documentation": "Product Rights [Member]" } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail", "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "auth_ref": [ "r292", "r845", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r1084", "r1101", "r1104", "r1106", "r1138", "r1139", "r1235", "r1236", "r1237", "r1240", "r1243", "r1356", "r1384", "r1385", "r1386", "r1387", "r1388", "r1389", "r1390", "r1391", "r1392", "r1393", "r1394", "r1395", "r1396", "r1397", "r1398", "r1399", "r1400", "r1401", "r1402", "r1403", "r1404", "r1405", "r1406", "r1407", "r1408", "r1409", "r1410", "r1411", "r1412", "r1413", "r1414", "r1415", "r1416", "r1417", "r1418", "r1419", "r1420", "r1422", "r1423", "r1424", "r1425", "r1496", "r1497", "r1609", "r1612", "r1613", "r1614", "r1615", "r1616", "r1617", "r1618", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1643", "r1644" ] }, "teva_ProfitFromSaleOfLongLivedAssetsAndInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ProfitFromSaleOfLongLivedAssetsAndInvestment", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 24.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Profit From Sale Of Long Lived Assets And Investment", "negatedLabel": "Net loss (gain) from sale of business and long-lived assets", "documentation": "Profit from sale of long lived assets and investment." } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 6.0 }, "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 25.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows", "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net income (loss)", "terseLabel": "Net income (loss)", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r142", "r147", "r172", "r175", "r197", "r200", "r205", "r206", "r208", "r220", "r229", "r232", "r233", "r332", "r425", "r426", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r467", "r551", "r587", "r649", "r651", "r654", "r655", "r747", "r778", "r889", "r891", "r906", "r964", "r1015", "r1032", "r1033", "r1191", "r1192", "r1258", "r1383", "r1501" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r14", "r799", "r894", "r904", "r1224" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r1297" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r1297" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeAxis", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail", "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical", "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Range [Axis]" } } }, "auth_ref": [ "r261", "r416", "r417", "r419", "r420", "r507", "r518", "r544", "r545", "r546", "r548", "r555", "r753", "r817", "r827", "r844", "r935", "r937", "r951", "r987", "r988", "r1039", "r1041", "r1043", "r1044", "r1054", "r1063", "r1064", "r1066", "r1067", "r1079", "r1080", "r1121", "r1137", "r1153", "r1155", "r1158", "r1159", "r1215", "r1216", "r1220", "r1221", "r1236", "r1246", "r1489", "r1503", "r1574", "r1601", "r1602", "r1603", "r1604", "r1605" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RangeMember", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail", "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical", "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "auth_ref": [ "r261", "r416", "r417", "r419", "r420", "r507", "r518", "r544", "r545", "r546", "r548", "r555", "r753", "r817", "r827", "r844", "r935", "r937", "r951", "r987", "r988", "r1039", "r1041", "r1043", "r1044", "r1054", "r1063", "r1064", "r1066", "r1067", "r1079", "r1080", "r1121", "r1137", "r1153", "r1155", "r1158", "r1159", "r1215", "r1216", "r1220", "r1221", "r1236", "r1246", "r1489", "r1503", "r1574", "r1601", "r1602", "r1603", "r1604", "r1605" ] }, "teva_RebatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "RebatesMember", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "Rebates [Member]", "terseLabel": "Rebates [Member]", "documentation": "Rebates." } } }, "auth_ref": [] }, "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" ], "lang": { "en-us": { "role": { "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent", "negatedLabel": "Amounts reclassified to the statements of income", "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": [ "r24" ] }, "us-gaap_ReclassificationTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ReclassificationTypeAxis", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Reclassification, Type [Axis]", "documentation": "Information by type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r1367" ] }, "us-gaap_ReclassificationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ReclassificationTypeDomain", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Reclassification, Type [Domain]", "documentation": "Type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r1367" ] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract", "lang": { "en-us": { "role": { "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable", "presentation": [ "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]", "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r35", "r36" ] }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://www.tevapharm.com/role/SegmentsTables" ], "lang": { "en-us": { "role": { "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Summary of Segment Profit", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment." } } }, "auth_ref": [ "r35", "r36" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r1265", "r1275", "r1285", "r1317" ] }, "teva_RegulatoryPriceAndVolumeOfProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "RegulatoryPriceAndVolumeOfProductsMember", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Regulatory Price And Volume Of Products [Member]", "terseLabel": "Regulatory Price And Volume Of Products [Member]", "documentation": "Regulatory price and volume of products." } } }, "auth_ref": [] }, "teva_ReleaseOfCumulativeTranslationAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ReleaseOfCumulativeTranslationAdjustments", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail" ], "lang": { "en-us": { "role": { "label": "Release of cumulative translation adjustments", "documentation": "Release of cumulative translation adjustments." } } }, "auth_ref": [] }, "teva_RepaymentsOfConvertibleDebentures": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "RepaymentsOfConvertibleDebentures", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments Of Convertible Debentures", "verboseLabel": "Repayment of convertible debentures", "documentation": "Repayments of convertible debentures." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 9.0 } }, "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r91" ] }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RepaymentsOfOtherLongTermDebt", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Other Long-Term Debt", "negatedLabel": "Repayment of senior notes and loans and other long-term liabilities", "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer." } } }, "auth_ref": [ "r91" ] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Repayments of Short-Term Debt", "verboseLabel": "Repayments of convertible senior debentures", "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r91" ] }, "us-gaap_ReportingUnitAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ReportingUnitAxis", "presentation": [ "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Reporting Unit [Axis]", "documentation": "Information by reporting unit." } } }, "auth_ref": [ "r361", "r363", "r1123" ] }, "us-gaap_ReportingUnitDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ReportingUnitDomain", "presentation": [ "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Reporting Unit [Domain]", "documentation": "Level of reporting at which goodwill is tested for impairment." } } }, "auth_ref": [ "r361", "r363", "r1123" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r200", "r209", "r210", "r440", "r481", "r807", "r828", "r897", "r1094", "r1096", "r1097", "r1370", "r1371", "r1372", "r1373", "r1374", "r1375", "r1376", "r1377", "r1378", "r1563", "r1564", "r1565", "r1566" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned", "terseLabel": "Reimbursement of research and development expenses incurred", "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r556" ] }, "teva_ResearchAndDevelopmentExpenseAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ResearchAndDevelopmentExpenseAndLiabilities", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 28.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Research And Development Expense And Liabilities", "terseLabel": "Acquired IPR&D related to Emalex Biosciences, see note 2", "documentation": "Research and development expense and liabilities." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "verboseLabel": "Research and development expenses", "terseLabel": "R&D expenses", "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r1536" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "teva_ReservesIncludedInAccountsReceivableNetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ReservesIncludedInAccountsReceivableNetMember", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "Reserves Included In Accounts Receivable Net [Member]", "terseLabel": "Reserves Included in Accounts Receivable, net [Member]", "documentation": "Reserves included in accounts receivable net." } } }, "auth_ref": [] }, "teva_RespiratoryProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "RespiratoryProductMember", "presentation": [ "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "Respiratory Product [Member]", "terseLabel": "Respiratory Product [Member]", "documentation": "Respiratory product." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r1266", "r1276", "r1286", "r1318" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r1267", "r1277", "r1287", "r1319" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r1274", "r1284", "r1294", "r1326" ] }, "teva_RestructuringAccrualProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "RestructuringAccrualProvision", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "label": "Restructuring Accrual Provision", "negatedLabel": "Provision", "documentation": "Restructuring Accrual Provision" } } }, "auth_ref": [] }, "teva_RestructuringAndImpairmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "RestructuringAndImpairmentAbstract", "lang": { "en-us": { "role": { "label": "Restructuring And Impairment [Abstract]", "documentation": "Restructuring and impairment." } } }, "auth_ref": [] }, "teva_RestructuringAndImpairmentCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "RestructuringAndImpairmentCostsLineItems", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" ], "lang": { "en-us": { "role": { "label": "Restructuring And Impairment Costs [Line Items]", "terseLabel": "Restructuring and Impairment Costs [Line Items]", "documentation": "Restructuring and impairment costs." } } }, "auth_ref": [] }, "teva_RestructuringAndImpairmentCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "RestructuringAndImpairmentCostsTable", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" ], "lang": { "en-us": { "role": { "label": "Restructuring And Impairment Costs [Table]", "terseLabel": "Restructuring And Impairment Costs [Table]", "documentation": "Restructuring And Impairment Costs [Table]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail": { "parentTag": "teva_ImpairmentAndRestructuring", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsScheduleOfOtherAssetsImpairmentsRestructuringAndOtherItemsDetail" ], "lang": { "en-us": { "role": { "label": "Restructuring Charges", "verboseLabel": "Restructuring", "terseLabel": "Restructuring charges", "positiveLabel": "Restructuring costs", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r12", "r188", "r190", "r409", "r410", "r1103", "r1491" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r188", "r190", "r405", "r406", "r410", "r411", "r1103" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r405", "r406", "r407", "r408", "r410", "r411", "r412" ] }, "teva_RestructuringExpenseAndIncome": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "RestructuringExpenseAndIncome", "presentation": [ "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Restructuring expense and income", "terseLabel": "Restructuring expense and income", "documentation": "Restructuring expense and income" } } }, "auth_ref": [] }, "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges." } } }, "auth_ref": [ "r1349", "r1350" ] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "label": "Restructuring Reserve", "negatedPeriodStartLabel": "Beginning balance", "negatedPeriodEndLabel": "Ending balance", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r406", "r411" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 33.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r72", "r110", "r901", "r945", "r950", "r961", "r997", "r1224" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RetainedEarningsMember", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r134", "r141", "r142", "r217", "r218", "r219", "r221", "r229", "r231", "r233", "r333", "r336", "r389", "r466", "r551", "r569", "r570", "r583", "r584", "r585", "r588", "r648", "r649", "r723", "r726", "r727", "r730", "r745", "r794", "r796", "r941", "r943", "r965", "r1649" ] }, "teva_ReturnsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ReturnsMember", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "Returns [Member]", "terseLabel": "Returns [Member]", "documentation": "Returns." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail", "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "verboseLabel": "Net revenues", "positiveTerseLabel": "Total revenue", "positiveLabel": "Revenues", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r122", "r123", "r255", "r267", "r268", "r283", "r289", "r292", "r294", "r296", "r503", "r504", "r505", "r845", "r1102", "r1106" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue from contracts with customers", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r130", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r505", "r506" ] }, "us-gaap_RevenueRecognitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevenueRecognitionAbstract", "lang": { "en-us": { "role": { "label": "Revenue Recognition [Abstract]" } } }, "auth_ref": [] }, "teva_RevenueRecognitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "RevenueRecognitionLineItems", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition [Line Items]", "terseLabel": "Revenue Recognition [Line Items]", "documentation": "Revenue Recognition [Line Items]" } } }, "auth_ref": [] }, "teva_RevenueRecognitionTable": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "RevenueRecognitionTable", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition [Table]", "terseLabel": "Revenue Recognition [Table]", "documentation": "Revenue Recognition [Table]" } } }, "auth_ref": [] }, "teva_RevenueTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "RevenueTypeAxis", "presentation": [ "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "Revenue Type [Axis]" } } }, "auth_ref": [] }, "teva_RevenueTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "RevenueTypeDomain", "presentation": [ "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "Revenue Type [Domain]" } } }, "auth_ref": [] }, "teva_RevenuesOtherThanUsd": { "xbrltype": "percentItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "RevenuesOtherThanUsd", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Revenues Other Than Usd", "terseLabel": "Revenues other than USD", "documentation": "Revenues other than US Dollar." } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "teva_RichardDFrancisPresidentAndCeoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "RichardDFrancisPresidentAndCeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Richard D. Francis, President and CEO [Member]" } } }, "auth_ref": [] }, "teva_RoyaltyPharmaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "RoyaltyPharmaMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Royalty Pharma [Member]", "terseLabel": "Royalty Pharma [Member]", "documentation": "Royalty pharma." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r1335" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r1335" ] }, "teva_SPVAmendmentAgreementOctoberTwoThousandAndTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SPVAmendmentAgreementOctoberTwoThousandAndTwentyFourMember", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "SPV Amendment Agreement October Two Thousand And Twenty Four [Member]" } } }, "auth_ref": [] }, "teva_SalesReservesAndAllowances": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SalesReservesAndAllowances", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Sales Reserves And Allowances", "terseLabel": "Sales reserves and allowances", "documentation": "The sum of the balance sheet amounts of the allowances for chargebacks, returns, rebates, other promotional items and price protection." } } }, "auth_ref": [] }, "teva_SalesReservesAndAllowancesCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SalesReservesAndAllowancesCurrentTableTextBlock", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables" ], "lang": { "en-us": { "role": { "label": "Sales Reserves And Allowances Current [Table Text Block]", "terseLabel": "Summary of Sales Reserves and Allowances", "documentation": "Tabular disclosure of sales reserves and allowances current." } } }, "auth_ref": [] }, "teva_SalesReservesAndAllowancesToCustomersPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SalesReservesAndAllowancesToCustomersPercentage", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Sales Reserves and Allowances to Customers Percentage", "terseLabel": "Percentage sales reserves and allowances to U.S. customers", "documentation": "Sales reserves and allowances to customers percentage." } } }, "auth_ref": [] }, "teva_SanofiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SanofiMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Sanofi [Member]", "terseLabel": "Sanofi [Member]", "documentation": "Sanofi." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Scenario, Unspecified [Domain]" } } }, "auth_ref": [ "r143", "r144", "r234", "r519", "r1351" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Accumulated Other Comprehensive Income/(Loss) (Net of Tax)", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r24", "r1591", "r1592" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.tevapharm.com/role/EarningsLossPerShareAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r251" ] }, "teva_ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ScheduleOfAssetsAndLiabilitiesHeldForSaleTableTextBlock", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Assets And Liabilities Held For Sale [Table Text Block]", "terseLabel": "Summary of Major Classes of Assets and Liabilities Included as Held for Sale", "documentation": "Schedule Of Assets And Liabilities Held For Sale [Table Text Block]" } } }, "auth_ref": [] }, "teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock", "presentation": [ "http://www.tevapharm.com/role/SegmentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Consolidated Income Before Income Tax [Table Text Block]", "terseLabel": "Schedule Of Consolidated Income Before Income Tax", "documentation": "Schedule of consolidated income before income tax." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Summary of Classification and Fair Values of Derivative Instruments", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r670", "r673", "r696", "r1206" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.tevapharm.com/role/EarningsLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings per Share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1443" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "presentation": [ "http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method." } } }, "auth_ref": [ "r238", "r239", "r248", "r250" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Financial Items Carried at Fair Value", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1571", "r1572" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r372", "r379", "r381", "r382", "r386", "r846", "r1082", "r1086", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Summary of Identifiable Intangible Assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r1086", "r1480" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail", "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": [ "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r363", "r1123" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.tevapharm.com/role/GoodwillTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Summary of Changes in the Carrying Amount of Goodwill by Segment", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r1123", "r1463", "r1464", "r1465", "r1466", "r1467", "r1468", "r1469", "r1470", "r1471", "r1472", "r1473" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.tevapharm.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Summary of Inventories", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r13", "r76", "r77", "r78" ] }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesTables" ], "lang": { "en-us": { "role": { "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "terseLabel": "Summary of Pre-tax (Gains) Losses From Derivatives Not Designated in as Hedging Instruments", "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument." } } }, "auth_ref": [ "r1553", "r1555", "r1556", "r1562" ] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Product Information [Table]", "terseLabel": "Schedule of Product Information [Table]", "documentation": "Disclosure of information about concentration risk of product within nature of operation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": [ "r405", "r406", "r407", "r408", "r410", "r411", "r412" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Summary of Restructuring Accruals", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r40", "r100", "r101" ] }, "teva_ScheduleOfRestructuringChargesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ScheduleOfRestructuringChargesTableTextBlock", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Restructuring Charges [Table Text Block]", "terseLabel": "Summary of Restructuring Plan Including Costs Related to Exit and Disposal", "documentation": "Schedule of Restructuring Charges [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Schedule of Other Assets Impairments, Restructuring and Other Items", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r41", "r102" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail", "http://www.tevapharm.com/role/SegmentsParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r32", "r33", "r34" ] }, "us-gaap_ScheduleOfShortTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ScheduleOfShortTermDebtTextBlock", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-term Debt [Table Text Block]", "terseLabel": "Schedule of Short-term Debt", "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r60" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1260" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r1262" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentDomain", "presentation": [ "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail", "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail", "http://www.tevapharm.com/role/SegmentsParentheticalDetail", "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "terseLabel": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r122", "r123", "r124", "r125", "r255", "r263", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r279", "r280", "r281", "r283", "r284", "r285", "r286", "r287", "r289", "r290", "r291", "r296", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r386", "r408", "r412", "r638", "r641", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r1112", "r1115", "r1116", "r1123", "r1239", "r1609", "r1612", "r1613", "r1614", "r1615", "r1616", "r1617", "r1618", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1643", "r1644" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail", "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "auth_ref": [ "r260", "r294", "r295", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r889", "r890", "r891", "r892", "r980", "r983", "r985", "r1040", "r1042", "r1045", "r1055", "r1063", "r1065", "r1066", "r1067", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1085", "r1108", "r1138", "r1140", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1238", "r1246", "r1609", "r1612", "r1613", "r1615", "r1616", "r1617", "r1618", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1643", "r1644" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription", "presentation": [ "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description", "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource." } } }, "auth_ref": [ "r282", "r1112", "r1118" ] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.tevapharm.com/role/Segments" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segments", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r125", "r255", "r262", "r263", "r264", "r265", "r266", "r278", "r280", "r281", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r296", "r1111", "r1113", "r1114", "r1115", "r1117", "r1119", "r1120" ] }, "us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingExpenseInformationUsedByCodmDescription", "presentation": [ "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Expense Information Used by CODM, Description", "documentation": "Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed." } } }, "auth_ref": [ "r255", "r281", "r289" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail", "http://www.tevapharm.com/role/SegmentsParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems", "presentation": [ "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense", "verboseLabel": "Selling and marketing expenses", "terseLabel": "S&M expenses", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SeniorNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SeniorNotes", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail" ], "lang": { "en-us": { "role": { "label": "Senior Notes", "verboseLabel": "Total senior notes", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders." } } }, "auth_ref": [ "r117", "r1608" ] }, "teva_SeniorNotesAndSustainabilityLinkedSeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SeniorNotesAndSustainabilityLinkedSeniorNotesMember", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Senior Notes And Sustainability Linked Senior Notes [Member]", "verboseLabel": "Senior Notes And Sustainability Linked Senior Notes [Member]", "documentation": "Senior notes and sustainability linked senior notes." } } }, "auth_ref": [] }, "us-gaap_SeniorNotesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SeniorNotesCurrent", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail" ], "lang": { "en-us": { "role": { "label": "Senior Notes, Current", "negatedLabel": "Less current maturities", "documentation": "Carrying value as of the balance sheet date of the portion of long-term notes having the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment." } } }, "auth_ref": [ "r61", "r1224" ] }, "teva_SeniornotesEUR1000MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SeniornotesEUR1000MillionMember", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Senior notes EUR 1000 Million [Member]" } } }, "auth_ref": [] }, "teva_SeniornotesUSD500millionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SeniornotesUSD500millionMember", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Senior notes USD 500 million [Member]" } } }, "auth_ref": [] }, "teva_SeniornotesUSD700millionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SeniornotesUSD700millionMember", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Senior notes USD 700 million [Member]" } } }, "auth_ref": [] }, "teva_SeniornotesandconvertibleseniordebenturesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SeniornotesandconvertibleseniordebenturesMember", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialInstrumentMeasuredOnABasisOtherThanFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Seniornotesandconvertibleseniordebentures [Member]", "terseLabel": "Senior Notes and Convertible Senior Debentures Included Under Short-Term Debt [Member]", "documentation": "Senior notes and convertible senior debentures." } } }, "auth_ref": [] }, "us-gaap_SettledLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SettledLitigationMember", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Settled Litigation [Member]", "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval." } } }, "auth_ref": [ "r1493" ] }, "teva_SettlementAsAPercentageOfAggregateSubdivisionsAndTribes": { "xbrltype": "percentItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SettlementAsAPercentageOfAggregateSubdivisionsAndTribes", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Settlement As A Percentage Of Aggregate Subdivisions And Tribes", "terseLabel": "Settlement as a percentage of aggregate subdivisions and tribes", "documentation": "Settlement as a percentage of aggregate subdivisions and tribes." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 26.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r11" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r543", "r544", "r545", "r546", "r547" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SharesIssued", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Shares, Issued", "periodStartLabel": "Beginning balance, shares", "periodEndLabel": "Ending balance, shares", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r17" ] }, "teva_ShortCreditAgreement2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ShortCreditAgreement2026Member", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "Short Credit Agreement 2026 [Member]", "terseLabel": "Convertible senior debentures [Member]", "documentation": "Short credit agreement 2026." } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShortTermBorrowings", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "Short-term Debt", "verboseLabel": "Convertible debentures", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r58", "r116", "r1224", "r1607" ] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r60", "r1486", "r1487", "r1488" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r58", "r1486", "r1487", "r1488" ] }, "us-gaap_ShortTermDebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ShortTermDebtWeightedAverageInterestRate", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Weighted Average Interest Rate, at Point in Time", "definitionGuidance": "Weighted average interest rate", "documentation": "Weighted average interest rate of short-term debt outstanding calculated at point in time." } } }, "auth_ref": [ "r59", "r424" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail", "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail", "http://www.tevapharm.com/role/SegmentsParentheticalDetail", "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "terseLabel": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r122", "r123", "r124", "r125", "r145", "r255", "r263", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r279", "r280", "r281", "r283", "r284", "r285", "r286", "r287", "r289", "r290", "r291", "r296", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r386", "r392", "r408", "r412", "r638", "r641", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r1112", "r1115", "r1116", "r1123", "r1239", "r1609", "r1612", "r1613", "r1614", "r1615", "r1616", "r1617", "r1618", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1643", "r1644" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r131", "r157", "r158", "r159", "r200", "r206", "r238", "r239", "r248", "r250", "r257", "r258", "r332", "r425", "r428", "r429", "r430", "r434", "r435", "r468", "r469", "r471", "r472", "r474", "r476", "r479", "r480", "r483", "r486", "r493", "r778", "r957", "r958", "r959", "r960", "r965", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r996", "r1016", "r1034", "r1056", "r1057", "r1058", "r1059", "r1060", "r1346", "r1432", "r1434", "r1442" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossDetail", "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail", "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r17", "r70", "r73", "r74", "r134", "r141", "r142", "r177", "r178", "r179", "r217", "r218", "r219", "r221", "r229", "r231", "r233", "r256", "r333", "r336", "r389", "r466", "r494", "r551", "r569", "r570", "r583", "r584", "r585", "r588", "r648", "r649", "r723", "r725", "r726", "r727", "r728", "r730", "r731", "r732", "r733", "r734", "r745", "r784", "r786", "r787", "r788", "r789", "r790", "r794", "r796", "r806", "r909", "r941", "r942", "r943", "r965", "r1034" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail", "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail", "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "auth_ref": [ "r260", "r294", "r295", "r848", "r849", "r850", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r889", "r890", "r891", "r892", "r980", "r983", "r985", "r1040", "r1042", "r1045", "r1055", "r1063", "r1065", "r1066", "r1067", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1085", "r1108", "r1138", "r1140", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1234", "r1238", "r1246", "r1609", "r1612", "r1613", "r1615", "r1616", "r1617", "r1618", "r1619", "r1620", "r1621", "r1622", "r1623", "r1624", "r1625", "r1626", "r1627", "r1628", "r1629", "r1630", "r1631", "r1632", "r1633", "r1634", "r1635", "r1636", "r1637", "r1643", "r1644" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementLineItems", "presentation": [ "http://www.tevapharm.com/role/BasisOfPresentation", "http://www.tevapharm.com/role/CertainTransactions", "http://www.tevapharm.com/role/CertainTransactionsTables", "http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical", "http://www.tevapharm.com/role/DebtObligations", "http://www.tevapharm.com/role/DebtObligationsTables", "http://www.tevapharm.com/role/FairValueMeasurement", "http://www.tevapharm.com/role/FairValueMeasurementTables", "http://www.tevapharm.com/role/Goodwill", "http://www.tevapharm.com/role/GoodwillTables", "http://www.tevapharm.com/role/IdentifiableIntangibleAssets", "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsTables", "http://www.tevapharm.com/role/Inventories", "http://www.tevapharm.com/role/InventoriesTables", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomers", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersTables" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r217", "r218", "r219", "r256", "r468", "r469", "r471", "r474", "r796", "r845", "r956", "r966", "r977", "r989", "r990", "r991", "r992", "r993", "r994", "r996", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1009", "r1010", "r1011", "r1012", "r1013", "r1017", "r1018", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1034", "r1104", "r1106", "r1247", "r1648" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StatementScenarioAxis", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r143", "r144", "r234", "r519", "r1351", "r1352" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementTable", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLossParenthetical" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r217", "r218", "r219", "r256", "r299", "r468", "r469", "r471", "r474", "r796", "r845", "r956", "r966", "r977", "r989", "r990", "r991", "r992", "r993", "r994", "r996", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1009", "r1010", "r1011", "r1012", "r1013", "r1017", "r1018", "r1020", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1030", "r1031", "r1034", "r1104", "r1106", "r1247", "r1648" ] }, "us-gaap_StatutoryAccountingPracticesByJurisdictionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatutoryAccountingPracticesByJurisdictionAxis", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Jurisdiction [Axis]", "documentation": "Information by state or country of domicile in which statutory financial statements are required." } } }, "auth_ref": [ "r1638", "r1639", "r1640", "r1641", "r1642" ] }, "us-gaap_StatutoryAccountingPracticesJurisdictionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatutoryAccountingPracticesJurisdictionDomain", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statutory Accounting Practices, Jurisdiction [Domain]", "documentation": "State or country of domicile in which statutory financial statements are required." } } }, "auth_ref": [ "r1638", "r1639", "r1640", "r1641", "r1642" ] }, "teva_StatutoryActAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "StatutoryActAxis", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statutory Act [Axis]" } } }, "auth_ref": [] }, "teva_StatutoryActDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "StatutoryActDomain", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statutory Act [Domain]" } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r1269", "r1279", "r1289", "r1321" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [ "r1510", "r1511", "r1512", "r1513", "r1514", "r1515", "r1516", "r1517", "r1518", "r1519", "r1520", "r1521", "r1522", "r1523", "r1524", "r1525", "r1526", "r1527", "r1528", "r1529", "r1530", "r1531", "r1532", "r1533", "r1534", "r1535" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of Shares, shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r17", "r69", "r70", "r110", "r957", "r1034", "r1057" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of options by employees and vested RSUs", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r17", "r70", "r73", "r74", "r110" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 30.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Stockholders' equity attributable to Teva shareholders", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r70", "r73", "r74", "r95", "r998", "r1014", "r1035", "r1036", "r1224", "r1259", "r1430", "r1434", "r1435", "r1462", "r1590", "r1649" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Teva shareholders' equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 28.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r48", "r49", "r51", "r134", "r135", "r141", "r142", "r178", "r217", "r218", "r219", "r221", "r229", "r231", "r333", "r336", "r389", "r466", "r494", "r551", "r569", "r570", "r583", "r584", "r585", "r588", "r648", "r649", "r723", "r725", "r726", "r727", "r728", "r730", "r745", "r784", "r786", "r790", "r795", "r806", "r942", "r943", "r963", "r998", "r1014", "r1035", "r1036", "r1061", "r1241", "r1242", "r1258", "r1430", "r1434", "r1435", "r1462", "r1590", "r1649" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Accumulated other comprehensive income (loss)", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r107", "r478", "r480", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r492", "r494", "r719", "r736", "r1037", "r1038", "r1062" ] }, "us-gaap_SubsegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsegmentsAxis", "presentation": [ "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" ], "lang": { "en-us": { "role": { "label": "Subsegments [Axis]", "documentation": "Information by business subsegments." } } }, "auth_ref": [] }, "us-gaap_SubsegmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsegmentsDomain", "presentation": [ "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail" ], "lang": { "en-us": { "role": { "label": "Subsegments [Domain]", "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r791", "r810" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r791", "r810" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail", "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail", "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r791", "r810" ] }, "teva_SubsidiarySeniorNotesDue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SubsidiarySeniorNotesDue2026Member", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Subsidiary Senior Notes Due 2026 [Member]", "terseLabel": "Senior notes USD 3,500 million [Member]", "documentation": "subsidiary senior notes due 2026." } } }, "auth_ref": [] }, "teva_SubsidiarySeniorNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SubsidiarySeniorNotesDue2027Member", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Subsidiary Senior Notes Due 2027 [Member]", "terseLabel": "Senior notes EUR 700 million [Member]", "documentation": "Subsidiary senior notes due 2027." } } }, "auth_ref": [] }, "teva_SubsidiarySeniorNotesDue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SubsidiarySeniorNotesDue2028Member", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Subsidiary Senior Notes Due 2028 [Member]", "verboseLabel": "Senior notes USD 1,250 million [Member]", "documentation": "Subsidiary senior notes due 2028." } } }, "auth_ref": [] }, "teva_SubsidiarySeniorNotesDue2028OneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SubsidiarySeniorNotesDue2028OneMember", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Subsidiary Senior Notes Due 2028 One [Member]", "verboseLabel": "Senior notes EUR 750 million [Member]", "documentation": "Subsidiary Senior Notes Due 2028 One [Member]" } } }, "auth_ref": [] }, "teva_SubsidiarySeniorNotesDue2036Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SubsidiarySeniorNotesDue2036Member", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Subsidiary Senior Notes Due 2036 [Member]", "terseLabel": "Senior notes USD 789 million [Member]", "documentation": "Subsidiary senior notes due 2036." } } }, "auth_ref": [] }, "teva_SubsidiarySeniorNotesDue2046Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SubsidiarySeniorNotesDue2046Member", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Subsidiary Senior Notes Due 2046 [Member]", "terseLabel": "Senior notes USD 2,000 million [Member]", "documentation": "Subsidiary senior notes due 2046." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Non-cash\u00a0financing and investing activities:" } } }, "auth_ref": [] }, "us-gaap_SupplierFinanceProgramObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SupplierFinanceProgramObligation", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Supplier Finance Program, Obligation", "terseLabel": "Supplier finance program obligation", "documentation": "Amount of obligation for supplier finance program." } } }, "auth_ref": [ "r399", "r400", "r401", "r402", "r403", "r1124" ] }, "us-gaap_SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "SupplierFinanceProgramObligationStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes obligation for supplier finance program." } } }, "auth_ref": [ "r400" ] }, "teva_SustainabilityLinkedSeniorNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SustainabilityLinkedSeniorNotesDue2027Member", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Sustainability Linked Senior Notes Due 2027 [Member]", "terseLabel": "Sustainability-linked senior notes USD 1,000 million [Member]", "documentation": "Sustainability linked senior notes due 2027." } } }, "auth_ref": [] }, "teva_SustainabilityLinkedSeniorNotesDue2027OneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SustainabilityLinkedSeniorNotesDue2027OneMember", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Sustainability Linked Senior Notes Due 2027 One [Member]", "terseLabel": "Sustainability-linked senior notes EUR 1,100 million [Member]", "documentation": "Sustainability linked senior notes due 2027 one." } } }, "auth_ref": [] }, "teva_SustainabilityLinkedSeniorNotesDue2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SustainabilityLinkedSeniorNotesDue2029Member", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Sustainability Linked Senior Notes Due 2029 [Member]", "verboseLabel": "Sustainability-linked senior notes USD 1,000 million [Member]", "terseLabel": "Sustainability-linked senior notes USD 1,000 million [Member]", "documentation": "Sustainability linked senior notes due 2029." } } }, "auth_ref": [] }, "teva_SustainabilityLinkedSeniorNotesDue2029OneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SustainabilityLinkedSeniorNotesDue2029OneMember", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Sustainability Linked Senior Notes Due 2029 One [Member]", "verboseLabel": "Sustainability-linked senior notes USD 600 million [Member]", "terseLabel": "Sustainability-linked senior notes USD 600\u00a0million [Member]", "documentation": "Sustainability linked senior notes due 2029 one." } } }, "auth_ref": [] }, "teva_SustainabilityLinkedSeniorNotesDue2029TwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SustainabilityLinkedSeniorNotesDue2029TwoMember", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Sustainability Linked Senior Notes Due 2029 Two [Member]", "verboseLabel": "Sustainability-linked senior notes EUR 800 million [Member]", "terseLabel": "Sustainability-linked senior notes EUR 800 million [Member]", "documentation": "Sustainability linked senior notes due 2029 two." } } }, "auth_ref": [] }, "teva_SustainabilityLinkedSeniorNotesDue2030Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SustainabilityLinkedSeniorNotesDue2030Member", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Sustainability Linked Senior Notes Due 2030 [Member]", "verboseLabel": "Sustainability-linked senior notes EUR 1,500 million [Member]", "terseLabel": "Sustainability-linked senior notes EUR 1,500 million [Member]", "documentation": "Sustainability linked senior notes due 2030." } } }, "auth_ref": [] }, "teva_SustainabilityLinkedSeniorNotesDue2031Member": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SustainabilityLinkedSeniorNotesDue2031Member", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Sustainability Linked Senior Notes Due 2031 [Member]", "verboseLabel": "Sustainability-linked senior notes USD 500 million [Member]", "documentation": "sustainability linked senior notes due 2031." } } }, "auth_ref": [] }, "teva_SustainabilityLinkedSeniorNotesDue2031OneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "SustainabilityLinkedSeniorNotesDue2031OneMember", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Sustainability Linked Senior Notes Due 2031 One [Member]", "verboseLabel": "Sustainability-linked senior notes EUR 500 million [Member]", "documentation": "Sustainability linked senior notes due 2031 one." } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r1315" ] }, "us-gaap_TangibleAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TangibleAssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tangible Asset Impairment Charges", "verboseLabel": "Impairments of property, plant and equipment", "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value." } } }, "auth_ref": [ "r56", "r98" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r568" ] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r568" ] }, "us-gaap_TaxPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TaxPeriodAxis", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tax Period [Axis]", "terseLabel": "Tax Period [Axis]", "documentation": "Information by period subject to enacted tax law." } } }, "auth_ref": [ "r1539" ] }, "us-gaap_TaxPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TaxPeriodDomain", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tax Period [Domain]", "terseLabel": "Tax Period [Domain]", "documentation": "Identified tax period." } } }, "auth_ref": [ "r1539" ] }, "teva_TermOfRoyaltyPayment": { "xbrltype": "durationItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "TermOfRoyaltyPayment", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Term Of Royalty Payment", "terseLabel": "Term of royalty payment", "documentation": "Term of royalty payment." } } }, "auth_ref": [] }, "teva_TevasApiBusinessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "TevasApiBusinessMember", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tevas API Business [Member]", "terseLabel": "Teva's API business [Member]", "documentation": "Teva's API business." } } }, "auth_ref": [] }, "us-gaap_TextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TextBlockAbstract", "lang": { "en-us": { "role": { "label": "Text Block [Abstract]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r1456", "r1597" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.tevapharm.com/role/SegmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "teva_TotalReservesIncludedInSalesReservesAndAllowancesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "TotalReservesIncludedInSalesReservesAndAllowancesMember", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "Total Reserves Included In Sales Reserves And Allowances [Member]", "terseLabel": "Total reserves included in sales reserves and allowances [Member]", "documentation": "Total reserves included in sales reserves and allowances." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r1307" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r1314" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TradeNamesMember", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsSummaryOfIdentifiableIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "label": "Trade Names [Member]", "terseLabel": "Trade names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r1161", "r1474", "r1475", "r1476", "r1477", "r1478", "r1479", "r1481", "r1482", "r1483", "r1484" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r1334" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r1336" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://www.tevapharm.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "teva_TrancheAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "TrancheAxis", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tranche [Axis]", "documentation": "Tranche." } } }, "auth_ref": [] }, "teva_TrancheDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "TrancheDomain", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Tranche [Domain]", "documentation": "Tranche." } } }, "auth_ref": [] }, "teva_TransactionsTerminationLossSettled": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "TransactionsTerminationLossSettled", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Transactions Termination Loss Settled", "terseLabel": "Transactions termination loss settled", "documentation": "Transactions termination loss settled." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFairValueOfFinancialLiabilitiesMeasuredUsingLevel3InputsDetail", "http://www.tevapharm.com/role/FairValueMeasurementSummaryOfFinancialItemsCarriedAtFairValueDetail" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r461", "r491", "r719", "r735", "r770", "r777", "r780", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r826", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r840", "r841", "r842", "r843", "r896", "r910", "r1210", "r1213", "r1215", "r1216", "r1217", "r1218", "r1219", "r1220", "r1221", "r1226", "r1360", "r1361", "r1362", "r1363", "r1364", "r1365", "r1366", "r1458", "r1459", "r1460", "r1461", "r1570", "r1573", "r1574", "r1575", "r1582", "r1585", "r1586", "r1587" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r1337" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r1338" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r1338" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1336" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r1336" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r1339" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r1337" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Shares [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r46" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r46" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 35.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury shares as of June\u00a030, 2026 and December\u00a031, 2025: 106\u00a0million ordinary shares and 107\u00a0million ordinary shares, respectively", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r46", "r47", "r70", "r73" ] }, "teva_TwoThousandAndTwentyFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "TwoThousandAndTwentyFiveMember", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Two Thousand And Twenty Five [Member]", "terseLabel": "Two Thousand And Twenty Five [Member]", "documentation": "Two thousand and twenty five." } } }, "auth_ref": [] }, "teva_TwoThousandAndTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "TwoThousandAndTwentyFourMember", "presentation": [ "http://www.tevapharm.com/role/CommitmentsAndContingenciesContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Two Thousand And Twenty Four [Member]", "terseLabel": "Two Thousand And Twenty Four [Member]", "documentation": "Two thousand and twenty four." } } }, "auth_ref": [] }, "teva_TwoThousandEightThroughTaxPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "TwoThousandEightThroughTaxPayableMember", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Two Thousand Eight Through Tax Payable [Member]", "terseLabel": "Two Thousand Eight Through Tax Payable [Member]", "documentation": "Two thousand eight through tax payable ." } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TypeOfAdoptionMember", "presentation": [ "http://www.tevapharm.com/role/AccumulatedOtherComprehensiveIncomeLossParentheticalDetail", "http://www.tevapharm.com/role/ConsolidatedStatementsOfChangesInEquityParenthetical", "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLossParenthetical" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": [ "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r193", "r194", "r195", "r220", "r221", "r222", "r223", "r224", "r234", "r297", "r298", "r333", "r334", "r335", "r336", "r388", "r389", "r404", "r464", "r465", "r466", "r467", "r549", "r550", "r551", "r552", "r569", "r570", "r571", "r572", "r573", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r625", "r626", "r627", "r645", "r646", "r647", "r648", "r649", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r771", "r772", "r794", "r795", "r801", "r802", "r803", "r804", "r805", "r806", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.tevapharm.com/role/CertainTransactionsOtherTransactionsAdditionalInformationDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r650" ] }, "us-gaap_TypeOfFreshStartAdjustmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TypeOfFreshStartAdjustmentDomain", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Type of Fresh-Start Adjustment [Domain]", "terseLabel": "Type of Fresh-Start Adjustment [Domain]", "documentation": "Adjustment for effect of reorganization under Chapter 11 of Bankruptcy Code. Includes, but is not limited to, adjustment for reorganization plan effect and adoption of fresh-start reporting." } } }, "auth_ref": [ "r808", "r809", "r1224" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsComponentsOfCostsAssociatedWithRestructuringPlanIncludingCostsRelatedToExitAndDisposalActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r188", "r190", "r405", "r406", "r410", "r411", "r1103" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "US", "presentation": [ "http://www.tevapharm.com/role/GoodwillSummaryOfChangesInTheCarryingAmountOfGoodwillBySegmentDetail", "http://www.tevapharm.com/role/LegalSettlementsAndLossContingenciesAdditionalInformationDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersAdditionalInformationDetail", "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersSummaryOfDisaggregationOfRevenuesByMajorRevenueStreamsDetail" ], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States [Member]" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r1333" ] }, "teva_UnitedStatesSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "UnitedStatesSegmentMember", "presentation": [ "http://www.tevapharm.com/role/SegmentsParentheticalDetail", "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail", "http://www.tevapharm.com/role/SegmentsSummaryOfSegmentProfitDetail" ], "lang": { "en-us": { "role": { "label": "United States Segment [Member]", "terseLabel": "United States [Member]", "documentation": "United States Segment [Member]" } } }, "auth_ref": [] }, "teva_UnrealizedGainLossOnCashFlowHedgingInstrument": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "UnrealizedGainLossOnCashFlowHedgingInstrument", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/DerivativeInstrumentsAndHedgingActivitiesSummaryOfPreTaxGainsLossesFromDerivativesDesignatedInCashFlowHedgingRelationshipsDetail" ], "lang": { "en-us": { "role": { "label": "Unrealized Gain (Loss) on Cash Flow Hedging Instrument", "terseLabel": "Financial expenses, net", "documentation": "Unrealized gain (loss) on cash flow hedging instrument." } } }, "auth_ref": [] }, "teva_UnrealizedGainLossOnDerivativeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "UnrealizedGainLossOnDerivativeNetOfTax", "crdr": "credit", "calculation": { "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Unrealized gain (loss) on derivative net of tax", "terseLabel": "Unrealized gain (loss) from derivative financial instruments, net", "documentation": "Unrealized gain (loss) on derivative net of tax." } } }, "auth_ref": [] }, "teva_UpdatedMarketAssumptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "UpdatedMarketAssumptionsMember", "presentation": [ "http://www.tevapharm.com/role/IdentifiableIntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Updated Market Assumptions [Member]", "terseLabel": "Updated Market Assumptions [Member]", "documentation": "Updated market assumptions ." } } }, "auth_ref": [] }, "teva_UtilizationAndOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "UtilizationAndOther", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/OtherAssetsImpairmentsRestructuringAndOtherItemsSummaryOfRestructuringAccrualsDetail" ], "lang": { "en-us": { "role": { "label": "Utilization And Other", "terseLabel": "Utilization and other", "documentation": "Utilization and other." } } }, "auth_ref": [] }, "teva_UzedyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "UzedyMember", "presentation": [ "http://www.tevapharm.com/role/SegmentsScheduleOfRevenuesByMajorProductsAndActivitiesDetail" ], "lang": { "en-us": { "role": { "label": "UZEDY [Member]", "terseLabel": "UZEDY [Member]" } } }, "auth_ref": [] }, "us-gaap_ValuationAllowancesAndReservesBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ValuationAllowancesAndReservesBalance", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "documentation": "Amount of valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r202", "r212", "r216" ] }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ValuationAllowancesAndReservesDeductions", "crdr": "debit", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedLabel": "Credits and payments", "documentation": "Amount of decrease in valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r202", "r215" ] }, "us-gaap_ValuationAllowancesAndReservesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ValuationAllowancesAndReservesDomain", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "documentation": "Valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r202", "r212", "r213", "r214", "r215", "r216" ] }, "teva_ValuationAllowancesAndReservesForeignCurrencyTranslation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ValuationAllowancesAndReservesForeignCurrencyTranslation", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "Valuation Allowances And Reserves Foreign Currency Translation", "terseLabel": "Translation differences", "documentation": "Valuation allowances and reserves foreign currency translation." } } }, "auth_ref": [] }, "teva_ValuationAllowancesAndReservesRelatedToCurrentPeriodSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ValuationAllowancesAndReservesRelatedToCurrentPeriodSales", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "Valuation Allowances And Reserves Related To Current Period Sales", "terseLabel": "Provisions related to sales made in current year period", "documentation": "Valuation allowances and reserves related to current period sales." } } }, "auth_ref": [] }, "teva_ValuationAllowancesAndReservesRelatedToPriorPeriodSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "ValuationAllowancesAndReservesRelatedToPriorPeriodSales", "crdr": "credit", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "Valuation Allowances And Reserves Related To Prior Period Sales", "terseLabel": "Provisions related to sales made in prior periods", "documentation": "Valuation allowances and reserves related to prior period sales." } } }, "auth_ref": [] }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ValuationAllowancesAndReservesTypeAxis", "presentation": [ "http://www.tevapharm.com/role/RevenueFromContractsWithCustomersScheduleOfSalesReservesAndAllowancesDetail" ], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "documentation": "Information by valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r202", "r212", "r213", "r214", "r215", "r216" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "VariableRateAxis", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [ "r1369", "r1500", "r1567" ] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "VariableRateDomain", "presentation": [ "http://www.tevapharm.com/role/DebtObligationsScheduleOfSeniorNotesAndLoansDetail", "http://www.tevapharm.com/role/DebtObligationsScheduleOfShortTermDebtDetail" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [ "r1369", "r1500", "r1567" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r1303" ] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "WeightedAverageMember", "presentation": [ "http://www.tevapharm.com/role/FairValueMeasurementAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average [Member]" } } }, "auth_ref": [ "r544", "r545", "r753", "r827", "r1079", "r1080", "r1215", "r1600", "r1602", "r1605" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted", "presentationGuidance": "Total dilutive shares outstanding", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r237", "r250" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average number of shares (in millions):" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.tevapharm.com/role/ConsolidatedStatementsOfIncomeLoss", "http://www.tevapharm.com/role/EarningsLossPerShareScheduleOfEarningsPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic", "verboseLabel": "Weighted average shares outstanding", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r236", "r250" ] }, "teva_YearOfSettlementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "YearOfSettlementAxis", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Year Of Settlement [Axis]", "terseLabel": "Year of settlement", "documentation": "Year of settlement." } } }, "auth_ref": [] }, "teva_YearOfSettlementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.tevapharm.com/20260730", "localname": "YearOfSettlementDomain", "presentation": [ "http://www.tevapharm.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Year Of Settlement [Domain]", "documentation": "Year of settlement." } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2025", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r1301" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-11" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-16" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-23" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "10", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SAB Topic 1.B.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-5" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-42" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-3A" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-5" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-5" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-6" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-6" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-4" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-7" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(24)(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480520/718-40-45-7" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480520/718-40-45-9" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EE", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EEE", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EEE", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4EEE", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4F", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4H" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4H" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4I" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4K", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4K", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4K", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4K", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4K", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4K", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4K", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4K", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "15", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480960/815-15-50-3" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481724/830-30-40-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r943": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r944": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r945": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r946": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r947": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r948": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r949": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r950": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r951": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r952": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1" }, "r953": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "805", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1" }, "r954": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r955": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r956": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r957": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r958": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r959": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r960": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r961": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r962": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r963": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r964": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r965": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r966": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6" }, "r967": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r968": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r969": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r970": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r971": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r972": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r973": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r974": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r975": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r976": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r977": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r978": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r979": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r980": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r981": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r982": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12" }, "r983": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r984": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r985": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r986": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r987": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r988": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r989": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r990": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r991": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r992": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r993": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r994": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r995": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r996": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r997": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r998": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r999": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1000": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1001": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1002": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1003": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1004": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1005": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1006": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1007": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1008": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1009": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1010": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1011": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1012": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1013": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r1014": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r1015": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r1016": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r1017": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1018": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1019": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1020": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1021": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1022": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1023": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1024": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1025": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1026": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1027": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1028": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1029": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1030": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1031": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1032": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r1033": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1034": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1035": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1036": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1037": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r1038": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r1039": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1040": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1041": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1042": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1043": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1044": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1045": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1046": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r1047": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r1048": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r1049": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r1050": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r1051": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r1052": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1053": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1054": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1055": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1056": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r1057": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1058": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1059": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1060": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r1061": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r1062": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r1063": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2" }, "r1064": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1065": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1066": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1067": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r1068": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r1069": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r1070": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1071": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1072": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1073": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1074": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1075": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1076": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1077": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1078": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1079": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r1080": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r1081": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r1082": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r1083": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10" }, "r1084": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1085": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r1086": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r1087": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1088": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1089": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1090": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1091": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1092": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1093": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15" }, "r1094": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r1095": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-20" }, "r1096": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r1097": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r1098": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r1099": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12" }, "r1100": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1101": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11" }, "r1102": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14" }, "r1103": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18" }, "r1104": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21" }, "r1105": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24" }, "r1106": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4" }, "r1107": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r1108": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18" }, "r1109": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1110": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r1111": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1112": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1113": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1114": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1115": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r1116": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r1117": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1118": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1119": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1120": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1121": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r1122": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r1123": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r1124": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477128/405-50-55-5" }, "r1125": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481899/410-30-55-16" }, "r1126": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1127": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1128": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1129": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1130": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r1131": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1132": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r1133": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r1134": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r1135": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r1136": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "64", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64" }, "r1137": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1138": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1139": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1140": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1141": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1142": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1143": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1144": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1145": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1146": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1147": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1148": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r1149": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r1150": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r1151": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1152": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1153": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r1154": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r1155": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8" }, "r1156": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "39", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-39" }, "r1157": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41" }, "r1158": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "43", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43" }, "r1159": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47" }, "r1160": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1161": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1162": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1163": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1164": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1165": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r1166": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r1167": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r1168": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r1169": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29" }, "r1170": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29" }, "r1171": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1172": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1173": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1174": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1175": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1176": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1177": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1178": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1179": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1180": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1181": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1182": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1183": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1184": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1185": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1186": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1187": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2" }, "r1188": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1" }, "r1189": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478064/805-740-55-13" }, "r1190": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r1191": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r1192": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r1193": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1194": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1195": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1196": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r1197": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r1198": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r1199": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r1200": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r1201": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r1202": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r1203": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r1204": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1205": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "181", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181" }, "r1206": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r1207": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "183", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-183" }, "r1208": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "184", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184" }, "r1209": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "185", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-185" }, "r1210": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1211": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1212": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1213": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r1214": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r1215": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r1216": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1217": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1218": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1219": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1220": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1221": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1222": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12" }, "r1223": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r1224": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r1225": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r1226": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r1227": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r1228": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r1229": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r1230": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r1231": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r1232": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r1233": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r1234": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r1235": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r1236": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r1237": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1238": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1239": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1240": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r1241": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11" }, "r1242": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14" }, "r1243": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r1244": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1245": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1246": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r1247": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1248": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1249": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1250": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1251": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1252": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r1253": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1254": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r1255": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r1256": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r1257": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r1258": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r1259": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r1260": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1261": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1262": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r1263": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r1264": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r1265": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r1266": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r1267": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1268": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1269": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1270": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1271": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1272": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r1273": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r1274": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r1275": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r1276": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r1277": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1278": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1279": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1280": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1281": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1282": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1283": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1284": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1285": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1286": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1287": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1288": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1289": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1290": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1291": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1292": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1293": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1294": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1295": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r1296": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1297": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r1298": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1299": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r1300": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r1301": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r1302": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r1303": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r1304": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r1305": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r1306": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r1307": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1308": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1309": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1310": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1311": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1312": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1313": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1314": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1315": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1316": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1317": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1318": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1319": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1320": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1321": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1322": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1323": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1324": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1325": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1326": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1327": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1328": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1329": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1330": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1331": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1332": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1333": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1334": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1335": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1336": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1337": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1338": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1339": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1340": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1341": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1342": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1343": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1344": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1345": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1346": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1347": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1348": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1349": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1350": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1351": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1352": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r1353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r1354": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r1355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r1356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1357": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1358": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "SubTopic": "310", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1359": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1360": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r1361": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r1362": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r1363": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r1364": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r1365": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r1366": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r1367": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r1368": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1369": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1370": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1371": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1372": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1373": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1374": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1375": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1376": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1377": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r1378": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12" }, "r1379": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15" }, "r1380": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r1381": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1382": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1383": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1384": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1385": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1386": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1387": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1388": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1389": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1390": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1391": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1392": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1393": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1394": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1395": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1396": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1397": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1398": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1399": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1400": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1401": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1402": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1403": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1404": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1405": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1406": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1407": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1408": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1409": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1410": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1411": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1412": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1413": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(r)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1414": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(s)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1415": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(t)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1416": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(u)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1417": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30" }, "r1418": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31" }, "r1419": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32" }, "r1420": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33" }, "r1421": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1422": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1423": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1424": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1425": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1426": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r1427": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1428": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1429": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r1430": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r1431": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r1432": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1433": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1434": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1435": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1436": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1437": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1438": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1439": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1440": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1441": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1442": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1443": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1444": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1445": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r1451": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1452": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1453": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1459": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1460": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1461": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1462": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1463": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1464": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1465": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1466": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1479": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1483": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1490": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-7" }, "r1491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r1492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r1494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480190/470-10-S50-1" }, "r1501": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1502": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1503": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1504": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-15" }, "r1505": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r1506": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1507": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1508": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1509": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r1510": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1511": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r1537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r1544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r1545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r1546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r1547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1" }, "r1549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1" }, "r1550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2" }, "r1551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r1556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC" }, "r1557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r1558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r1559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r1560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r1563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A" }, "r1564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r1568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r1569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r1587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r1588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r1589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1" }, "r1594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r1607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-1" }, "r1639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-1" }, "r1640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-1" }, "r1641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-3" }, "r1642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477908/944-505-50-5" }, "r1643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } }